Document:

Separation Agreement

 Exhibit 10.78 
 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. 
 Confidential Treatment Requested Under 
 17 C.F.R. Sections
200.80(b)(4) and 240.24b-2 
 SEPARATION AGREEMENT 
 This Separation Agreement (this “Agreement”) is entered into this 28th day of October, 2009 (the “Effective Date”) by and
between Syngenta Participations AG, a corporation organized under the laws of Switzerland (“Syngenta”) and Verenium Corporation (formerly Diversa Corporation), a Delaware corporation (“Verenium”). In this Agreement,
Syngenta and Verenium are referred to individually as a “Party” and collectively as the “Parties.” 
 Background 
 The Parties have undertaken collaborative research efforts since 1999 and are
currently operating under a License and Research Agreement, dated December 31, 2006 (the “LRA”), which agreement superseded the Amended and Restated Research Collaboration Agreement, by and between the Parties as of
January 3, 2003, as amended May 28, 2004 (the “Collaboration Agreement”). The Parties now desire to terminate the LRA and set forth their respective rights and obligations with respect to all biomolecules developed
pursuant to the LRA and the Collaboration Agreement. This Separation Agreement will supersede and replace in its entirety the LRA and the Collaboration Agreement. 
 1.        Definitions. 
 1.1      “[...***...]” means the protein sequence as disclosed in Patent Application number US [...***...]. 
 1.2      “Affiliate” means any corporation, firm, limited liability company,
partnership or other entity that directly or indirectly controls or is controlled by or is under common control with a Party to this Agreement. As used in this definition, control means ownership, directly or through one or more Affiliates, of more
than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or more than fifty percent (50%) of the equity interests in the case of any other type of legal entity, status as
a general partner in any partnership, or any other arrangement whereby a Party has the right to designate a majority of the board of directors or equivalent governing body of a corporation or other entity or otherwise has the right to control
management of such corporation or other entity, or if such level of ownership or control is prohibited in any country, any entity owning or controlling at the maximum control or ownership right permitted in the country where such entity exists.

 1.3      “[...***...] Project” means the research
project under the LRA for generating [...***...]. 
 1.4      “Animal Nutrition” means the use of Biomolecules in feed applications to alter, modify or improve feed conversion and/or animal nutrition, but excluding all vaccines and therapeutic
applications. 
 1.5      “Biomass” means material that
originates from Plants which can be or is intended to be used as a feedstock in the research, development and/or production of biofuels and bioproducts, including without limitation bioethanol, biodiesel, other fuels for energy applications and
chemicals for any purpose, including without limitation agricultural, food and non-food crops and their residues and wastes (e.g. normally non-food material from crops such as stalks, leaves, husks, seed fiber, hulls), forestry residues and wastes
(e.g. wood chips, sawdust, cardboard, pressboard, dead trees, tree branches), municipal solid waste (e.g. household garbage and paper products), food processing and other industrial 

 wastes, energy crops (e.g. fast growing trees and grasses grown for this purpose),
including, but not limited to, corn stover, switchgrass, and sugar cane bagasse, as well as trees; Biomass is often significantly composed of cellulose, hemi cellulose and lignin structures and may also include oil crops and starch components of
crops. 
 1.6      “Biomolecule” means any Gene, DNA, RNA, and
protein or chemical entity the synthesis of which is directed by such Gene or Gene pathway, which protein or chemical entity was produced by an organism. 
 1.7      “Collaboration Materials” means (i) any Biomolecule (a) discovered or identified under the research program conducted pursuant to the
terms of the Collaboration Agreement or the LRA or (b) otherwise delivered by Verenium to Syngenta pursuant to the terms of the LRA or the Collaboration Agreement, which Biomolecules are identified in Exhibit A and those variants of such
Biomolecules identified in the data and results arising out of the research and development program conducted pursuant to the LRA or the Collaboration Agreement, and (ii) all data, information and materials with respect to any Biomolecule
generated by Verenium pursuant to the terms of the LRA or the Collaboration Agreement, delivered by Verenium to Syngenta pursuant to the terms of the LRA or Collaboration Agreement, or obligated to be delivered by Verenium to Syngenta pursuant to
the LRA or the Collaboration Agreement or to be delivered by Syngenta to Verenium, as set forth in Exhibit F. For the avoidance of doubt, Collaboration Materials include, but are not limited to all such materials, data and information
described above: (a) and designated by the Parties as [...***...]; (b) developed for use in the field of Animal Nutrition; (c) pertaining to alpha and gluco amylases, commonly referred to by the Parties as
[...***...]; and (d) developed, delivered or evolved during the performance of the Joint Bagasse Project or continuing work on such project (i) by Verenium as of the Effective Date, or (ii) by Verenium in the course of
performance of the [...***...] Project between the Effective Date and termination of the [...***...] Project. 
 1.8      “Confidential Information” of a Party means any and all any confidential information of such Party or any data, technical and economic information
(including the economic terms hereof), commercialization, and research strategies and Know-How and other information provided by such Party during the performance of this Agreement, during the term of the LRA, during the term of the Collaboration
Agreement or during the negotiation of this Agreement, the Collaboration Agreement, the License Agreement or the Transaction Agreement or in connection with the transactions contemplated thereby, or any Patent Rights, Know-How and materials solely
owned by such Party or otherwise Controlled by such Party by virtue of rights granted by a Third Party furnished to the other Party by such Party pursuant to this Agreement, the LRA, the Collaboration Agreement, the License Agreement or the
Transaction Agreement or the transactions contemplated thereby. 
 1.9      “Control,” “Controls,” or “Controlled” means possession of the ability to grant the licenses or sublicenses as provided for herein (other than by virtue of any
license granted pursuant to this Agreement or the License Agreement) without violating the terms of any agreement or other arrangement with any third party. 
 1.10    “Disclosing Party” means the Party providing or disclosing the Confidential Information to the other Party. 
 1.11    “[...***...] Project” means the project [...***...].

  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 2	  	  

		  	  	

 1.12      “Gene” means a
polynucleotide sequence which can be transcribed into RNA and generally encodes a protein, optionally together with its regulatory sequences. 
 1.13      “Joint Bagasse Project” means the collaborative project directed to the conversion of sugar cane Biomass conducted pursuant to the terms of the
Collaboration Agreement and the LRA. 
 1.14      “Know-How”
means all proprietary ideas, inventions, data, instructions, processes, trade secrets, devices, methods, formulae, materials, protocols and marketing and other information, including improvements thereon, whether or not patentable, including,
without limitation, biological, chemical, toxicological, physical and analytical, safety, manufacturing and quality control data and information, which are (a) not publicly available and not covered by Patent Rights, but which (i) are
necessary or useful for the commercial exploitation of the Patent Rights or (ii) otherwise relate to Biomolecules or products that contain or incorporate Biomolecules or are manufactured or produced using Biomolecules, and (b) Controlled
by a Party or its Affiliate as of the Effective Date (including those based on or derived from information or inventions generated in the course of the research program conducted under the LRA or the Collaboration Agreement). 
 1.15      “[...***...] Project” the project performed under the LRA or
the Collaboration Agreement designated by the Parties as the [...***...] Project. 
 1.16      “License Agreement” means that certain Intellectual Property Rights License Agreement, dated as of December 3, 2002, between Verenium and Syngenta, as amended in accordance with
its terms. 
 1.17      “Microbial Expression” means a microbial
fermentation process for Biomolecules, including, without limitation, bacterial, fungal and yeast based fermentation. For avoidance of doubt, algae should not be considered a microbe for the purpose of the Agreement, and “Microbial Expression
“ shall not include expression in algae. 
 1.18      “Patent
Rights” means any United States or foreign patent or patent application, and any division, continuation, continuation-in-part, reissue, reexamination, extension or other governmental action that extends the subject matter of such patent or
patent application, substitution, confirmation, registration or revalidation of the foregoing, in each case, that claims a Biomolecule or a product which consists of, incorporates or is made through the use of such Biomolecule or a method or process
for the manufacture or use thereof and that is Controlled by Syngenta or Verenium or their respective Affiliates, or jointly by Syngenta and Verenium as of the Effective Date (including those inventions made in the course of the research program
conducted under the Collaboration Agreement or the LRA). 
 1.19      “Plant” means a monocotyledonous or dicotyledonous plant, or an angiosperm, a gymnosperm or a pteridophyte. For avoidance of doubt “Plants” shall not include algae.

 1.20      “Plant Gene” means a Gene which is native to a Plant
or a Gene modified for expression in Plants. 
 1.21      “Receiving
Party” means the Party to whom the Disclosing Party provides or discloses Confidential Information. 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 3	  	  

		  	  	

 1.22      “Sublicensee” means
(i) with respect to Syngenta, a Third Party which receives from Syngenta or its Affiliate a license or sublicense, and (ii) with respect to Verenium, a Third Party which receives from Verenium or its Affiliate a license or sublicense.

 1.23      “Syngenta Know-How” means any Know-How Controlled by
Syngenta or its Affiliates as of the Effective Date. 
 1.24      “Syngenta Patent Rights” means any Patent Rights Controlled by Syngenta or its Affiliates, including, without limitation, the Patent Rights specified in Section 10.1(a). Syngenta
Patent Rights shall not include the Assigned Patents or any Patent Rights that were assigned to Syngenta by Verenium pursuant to the LRA or the Collaboration Agreement as a result of Verenium’s decision not to file for or prosecute such Patent
Rights, which Patent Rights shall be owned solely and exclusively by Syngenta without further obligation to Verenium. 
 1.25      “Third Party” means any party other than Syngenta, Verenium or an Affiliate of either of them. 
 1.26      “TMRI Platform Technology” means all tools, technologies and methods relating to proteomics, metabolomics, RNA dynamics and
bioinformatics and methods to analyze and link these components of genomics, which are both (i) not publicly available and were proprietary to or Controlled by Syngenta or its Affiliates immediately prior to the closing of the transactions
under the Transaction Agreement, and (ii) claimed or disclosed within the patent applications and patents listed on Exhibit A to the License Agreement or are within the scope of the material trade secrets related thereto, a written
description of such material trade secrets having been previously provided by Syngenta prior to signing the Transaction Agreement. 
 1.27      TMRI Platform Technology Improvements” means any enhancement or improvement to the TMRI Platform Technology, whether or not patentable, made, conceived
or reduced to practice solely by any employee or consultant of Syngenta, solely by any employee or consultant of Verenium or jointly by any employee or consultant of Syngenta and any employee or consultant of Verenium at any time after the effective
date of the Collaboration Agreement, and all Patent Rights and Know-How that claim, disclose or cover such enhancement or improvement. 
 1.28      “Transaction Agreement” means that certain Transaction Agreement, dated as of December 3, 2002, among Torrey Mesa Research Institute, Verenium
and Syngenta, as amended in accordance with its terms. 
 1.29      “Transgenic Expression” means expression or production of Biomolecules in Plants or using Plant Genes. 
 1.30      “Verenium Know-How” means any Know-How Controlled by Verenium or its Affiliates as of the Effective Date. 
 1.31      “Verenium Patent Rights” means any Patent Rights Controlled by
Verenium or its Affiliates, including, without limitation, the Patent Rights specified in Section 10.1(b). 
 2.         Collaboration Material Rights.    The Parties acknowledge and agree that each of the Parties have the following rights with respect to the Collaboration
Materials: 
  

					
	  
	  	Page 4	  	  

		  	  	

 2.1      Syngenta Rights. Syngenta
shall retain all rights under the Syngenta Patent Rights and Syngenta Know-How, and Verenium hereby grants to Syngenta and its Affiliates a perpetual, irrevocable, royalty free, fully paid, exclusive, worldwide license, with the right to sublicense,
under the Verenium Patent Rights and Verenium Know-How, to make, have made and use Biomolecules included in the Collaboration Materials expressed or produced through Transgenic Expression and to use data and information included in the Collaboration
Materials, in each case to develop, have developed, use, have used, make, have made, import, have imported, export, have exported, sell, offer for sale and have sold products which consist of, incorporate or are made through the use of any
Biomolecules included in the Collaboration Materials expressed or produced through Transgenic Expression. 
           In addition, the Parties acknowledge and agree that Syngenta shall have a perpetual, irrevocable, royalty free, fully paid, exclusive, worldwide license, with the right to
sublicense, under the Verenium Patent Rights and Verenium Know-How, to make, have made and use[...***...] (also known as [...***...]) and to use data and information included in the Collaboration Materials, in each case to
develop, have developed, use, have used, make, have made, import, have imported, export, have exported, sell, offer for sale and have sold products which consist of, incorporate or are made through the use of [...***...]. 
            The rights of Syngenta and its Affiliates with respect to
the Collaboration Materials as set forth in this Section 2.1 and Section 2.3 and the rights of Syngenta described in Section 3 are referred to as the “Syngenta Rights.” 
           Verenium expressly agrees that no further milestones, royalties or
other payments shall be due to Verenium with respect to the exercise of any of the Syngenta Rights. In no event shall Syngenta’s commercialization or sublicensing of any Syngenta Rights or any of the Syngenta Patent Rights or Syngenta Know-How
trigger any additional fees or payment obligations from Syngenta to Verenium. The Parties agree that this paragraph does not limit any obligation of Syngenta for indemnification pursuant to Section 14 or for breach of this Agreement.

 2.2      Verenium Rights. Subject to the research license set forth in
Section 2.3 below, and to Section 2.1 above with respect to the exclusive rights to [...***...], Verenium shall retain all rights under the Verenium Patent Rights and Verenium Know-How, to make, have made and use the
Biomolecules included in the Collaboration Materials expressed or produced through Microbial Expression, and to use data and information included in the Collaboration Materials, in each case to use, develop, have developed, use, have used, make,
have made, import, have imported, export, have exported, sell, offer for sale and have sold products which consist of, incorporate or are made through the use of any Biomolecules included in the Collaboration Materials expressed or produced through
Microbial Expression. 
           In addition, Syngenta
hereby grants to Verenium and its Affiliates a perpetual, irrevocable, royalty free, fully paid, exclusive, worldwide license, with the right to sublicense, under the Syngenta Patent Rights and Syngenta Know-How, to make, have made and use
Biomolecules included in the Collaboration Materials expressed or produced through Microbial Expression and to use data and information included in the Collaboration Materials, in each case to develop, have developed, use, have used, make, have
made, import, have imported, export, have exported, sell, offer for sale and have sold products which consist of, incorporate or are made through the use of any Biomolecules included in the Collaboration Materials expressed or produced through
Microbial Expression. 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 5	  	  

		  	  	

           The rights of
Verenium and its Affiliates with respect to the Collaboration Materials as set forth in this Section 2.2 and the rights of Verenium described in Section 3 and with respect to Assigned Patents as set forth in Section 10.3 are referred
to as the “Verenium Rights.” 
           Syngenta expressly agrees that no milestones, royalties or other payments shall be due to Syngenta with respect to the exercise of the Verenium Rights or any improvements thereto.
In no event shall Verenium’s commercialization or sublicensing of any Verenium Rights or any of the Verenium Patent Rights or Verenium Know-How trigger any fees or payment obligations from Verenium to Syngenta. The Parties agree that this
paragraph does not limit any obligation of Verenium for indemnification pursuant to Section 14 or for breach of this Agreement. 
 2.3      Research Rights. Verenium hereby grants to Syngenta and its Affiliates a perpetual, royalty free, world-wide license, with the right to sublicense for the
purpose of conducting work by or on behalf of Syngenta or its Affiliates, under the Verenium Patent Rights and Verenium Know-How to develop, have developed, make, have made and use Biomolecules included in the Collaboration Materials expressed or
produced through Microbial Expression solely for the purpose of research and development of such Biomolecules for production or expression through Transgenic Expression pursuant to the license granted in Section 2.1. For clarification, in no
event shall Syngenta or its Affiliates have any license to commercialize any Biomolecules included in the Collaboration Materials expressed or produced through Microbial Expression or products based thereon. 
 2.4.      Joint Rights. Each of the Parties shall have a perpetual, irrevocable,
royalty free, fully paid, non-exclusive, worldwide license, with the right to sublicense, under the Verenium Patent Rights, the Verenium Know-How, the Syngenta Patent Rights and the Syngenta Know-How to make, have made and use Biomolecules included
in the Collaboration Materials expressed or produced through any form of expression or production of Biomolecules, other than Transgenic Expression and Microbial Expression, and to use data and information included in the Collaboration Materials, in
each case to develop, have developed, use, have used, make, have made, import, have imported, export, have exported, sell, offer for sale and have sold products which consist of, incorporate or are made through the use of any Biomolecules included
in the Collaboration Materials expressed or produced through any form of expression or production of Biomolecules other than Transgenic Expression and Microbial Expression. The joint rights set forth in this Section 2.4 shall specifically
include expression or production of Biomolecules in algae. 
 3.        Additional Rights. In addition to the rights set forth in Section 2 above and without changing any of the rights with respect to the Collaboration Materials as set forth in
Section 2.1 above: 
 3.1      TMRI Platform Technology Improvements.
The Parties hereby acknowledge and agree that (a) Verenium shall own all TMRI Platform Technology Improvements, and shall be entitled to use the foregoing for any purpose, subject to the provisions of Sections 10.1 and 3.1(b) with respect
to TMRI Platform Technology Improvements included in the data and results arising out of the research program conducted pursuant to the terms of the Collaboration Agreement or pursuant to Section 3 of the LRA, and (b) Verenium hereby
grants Syngenta and its Affiliates a perpetual, irrevocable, non-exclusive, royalty-free, worldwide license, with the right to sublicense, to use the TMRI Platform Technology Improvements which are owned or otherwise Controlled by Verenium pursuant
to Section 3.1(a) in the Syngenta Exclusive Field and in the Former Syngenta Exclusive Field (as such terms are defined in the LRA). 
  

					
	  
	  	Page 6	  	  

		  	  	

 3.2      [...***...] Project
and [...***...] Project. Verenium further acknowledges and agrees that Syngenta solely owns all right, title and interest in and to (i) all proprietary ideas, inventions, data, instructions, processes, trade
secrets, devices, methods, formulae, materials, protocols and marketing, information, software (including source code), documentation, hardware, designs, plans, apparatus, systems and the like (including, without limitation, the leaf sampling
platform) generated in the course of the [...***...] Project conducted by the Parties under the Collaboration Agreement and/or under the LRA, including all intellectual property rights therein; and (ii) all materials, Biomolecules,
proprietary ideas, inventions, data, processes, trade secrets, methods, formulae, materials protocols and the like generated in the course of the [...***...] Project conducted by the Parties under the Collaboration Agreement and/or
under the LRA, including all intellectual property rights therein. Verenium agrees to cooperate fully in the preparation, filing and prosecution of any intellectual property rights pursuant to this Section 3.2, including without limitation,
provide all materials (including assignments of rights, power of attorney, etc.) and information, and shall sign all documents and make all declarations necessary for Syngenta to apply for and pursue such intellectual property protection or to
otherwise reasonably assist Syngenta in its intellectual property-related activities. 
 4.      [...***...]. Syngenta has previously sublicensed Microbial Expression rights in certain of its Collaboration Materials to [...***...] pursuant to an exclusive license in all
fields excluding any plant expression systems, dated [...***...] (the “[...***...] Agreement”). Upon execution of this Agreement, the Parties hereby agree that the [...***...] Agreement shall be
assigned in its entirety to Verenium and Verenium hereby agrees to accept assignment of the [...***...] Agreement in full and to assume all Syngenta obligations, rights and responsibilities under the [...***...] Agreement
in accordance with the terms and conditions of the [...***...] Assignment Agreement attached hereto as Exhibit C, provided that Verenium shall not assume any liabilities or obligations of Syngenta under the
[...***...] Agreement that arose prior to the date of such assignment or that arise after the date of such assignment and relate to any breach by Syngenta of the [...***...] Agreement prior to such assignment date or any
event, circumstance or condition occurring or existing on or prior to such assignment date that, with notice or lapse of time, would constitute or result in a breach by Syngenta of the [...***...] Agreement. 
 5.      [...***...]. Syngenta entered into a Limited Exclusive Worldwide Patent
License Agreement for [...***...] Technology, dated [...***...], with [...***...] (the “[...***...] Agreement”) for Microbial Expression rights in and to the [...***...]
Collaboration Materials identified in Exhibit A as the “[...***...] Molecules.” Verenium has reviewed and consented to the terms and conditions of the [...***...] Agreement and hereby agrees that upon
execution of this Agreement, the [...***...] Agreement shall be assigned in its entirety to Verenium and Verenium hereby agrees to accept assignment of the [...***...] Agreement in full and to assume all Syngenta
obligations, rights and responsibilities under the [...***...] Agreement in accordance with the terms and conditions of the [...***...] Assignment Agreement attached hereto as Exhibit D, provided that Verenium shall
not assume any liabilities or obligations of Syngenta under the [...***...] Agreement that arose prior to the date of such assignment or that arise after the date of such assignment and relate to any breach by Syngenta of the
[...***...] Agreement prior to such assignment date or any event, circumstance or condition occurring or existing on or prior to such assignment date that, with notice or lapse of time, would constitute or result in a breach by Syngenta
of the [...***...] Agreement. The Parties further acknowledge and agree that pursuant to the terms and conditions of the [...***...]Agreement, Syngenta received an upfront payment in the amount of $[...***...].
Within thirty (30) days of the Effective Date, Syngenta shall deliver to Verenium by wire transfer a portion of such upfront payment equal to $[...***...]. Verenium agrees that Syngenta shall have no obligation to make any
additional payments to Verenium under the [...***...] Agreement, including but not limited to payments based on amounts received by Syngenta prior to the assignment of the [...***...] Agreement to Verenium, except
as set forth in this Section 5. 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 7	  	  

		  	  	

 6.        Improvements. 
 6.1      Syngenta Improvements. The Parties acknowledge and agree that Syngenta and its
Affiliates and Sublicensees and any party that acquires rights to any Biomolecule included in the Collaboration Material from Syngenta (the “Syngenta Parties”) shall have the right to optimize, enhance and modify any Biomolecules
included in the Collaboration Materials without payment or other obligations to Verenium. All such improvements to any Biomolecules included in the Collaboration Materials made by or on behalf of a Syngenta Party after the Effective Date of this
Agreement (“Syngenta Improvements”) shall be owned by such Syngenta Party, and such Syngenta Party shall have the right to file for patent rights on such Syngenta Improvements and shall control prosecution, maintenance, enforcement
and defense of any such patent rights in or to such Syngenta Improvements (“Syngenta Improvement Patent Rights”). 
 6.2      Verenium Improvements. The Parties acknowledge and agree that Verenium and its Affiliates and Sublicensees and any party that acquires rights to any
Biomolecule included in the Collaboration Material from Verenium (the “Verenium Parties”) shall have the right to optimize, enhance and modify any Biomolecules included in the Collaboration Materials without payment or other
obligations to Syngenta, other than the obligations set forth in this Agreement. All such improvements to any Biomolecules included in the Collaboration Materials made by or on behalf of a Verenium Party after the Effective Date of this Agreement
(“Verenium Improvements”) shall be owned by such Verenium Party, and such Verenium Party shall have the right to file for patent rights on such Verenium Improvements and shall control prosecution, maintenance, enforcement and
defense of any such patent rights in or to such Verenium Improvements (“Verenium Improvement Patent Rights”). Notwithstanding the foregoing, the Parties acknowledge and agree that modifications to Biomolecules that were developed in
the Joint Bagasse Project, which modifications are made in the course of performance of the [...***...] Project between the Effective Date and termination of the [...***...] Project shall be Biomolecules included in the
Collaboration Materials but shall not be considered Verenium Improvements. 
 6.3      Verenium Non-Assert. In the event that the practice of any Syngenta Improvement to use, develop, have developed, make, have made, import, have imported, export, have exported, sell offer for
sale and have sold products which consist of, incorporate or are made through the use of such Syngenta Improvement expressed or produced through Transgenic Expression would infringe (i) any Verenium Patent Rights, or (ii) any Verenium
Improvement Patent Rights that claim a Verenium Improvement that [...***...], then Verenium hereby covenants to Syngenta that Verenium and its Affiliates will not, and Verenium will cause the applicable Verenium Party that owns any
Verenium Improvement Patent Rights not to, assert or enforce such Verenium Patent Rights or such Verenium Improvement Patent Rights against any Syngenta Party solely with respect to the Syngenta Party’s manufacturing, having manufactured or
using such Syngenta Improvement to use, develop, have developed, make, have made, import, have imported, export, have exported, sell, offer for sale and have sold products which consist of, incorporate or are made through the use of any Syngenta
Improvement expressed or produced through Transgenic Expression. 
 6.4      Syngenta Non-Assert. In the event that the practice of any Verenium Improvement to use, develop, have developed, make, have made, import, have imported, export, have exported, sell offer for
sale and have sold products which consist of, incorporate or are made through the use of such Verenium Improvement expressed or produced through Microbial Expression would infringe (i) any Syngenta Patent Rights, or (ii) any Syngenta
Improvement Patent Rights that claim a Syngenta Improvement that 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 8	  	  

		  	  	

 
[...***...], then Syngenta hereby covenants to Verenium that Syngenta and its Affiliates will not, and Syngenta will cause the applicable Syngenta Party that owns any Syngenta
Improvement Patent Rights not to, assert or enforce such Syngenta Patent Rights or such Syngenta Improvement Patent Rights against any Verenium Party solely with respect to such Verenium Party’s manufacturing, having manufactured or using such
Verenium Improvement to use, develop, have developed, make, have made, import, have imported, export, have exported, sell, offer for sale and have sold products which consist of, incorporate or are made through the use of any Verenium Improvement
expressed or produced through Microbial Expression. 
 7.      Material
Production. Verenium hereby agrees that for a period of [...***...] from the Effective Date, Verenium shall continue to supply Syngenta with sufficient quantities of Biomolecules listed on Exhibit A as reasonably necessary
for Syngenta to exercise the Syngenta Rights. Verenium shall, upon request by Syngenta, supply such Biomolecules to Syngenta at [...***...] and Syngenta shall pay Verenium such amount within thirty (30) days after the date of an
undisputed invoice for such amount. In an effort to transition the supply of Biomolecules within the Collaboration Materials from Verenium to a third party supplier identified by Syngenta, Verenium will provide Syngenta with the following
information with regard to the manufacturing process used by Verenium with regard to such Biomolecules within the Collaboration Materials: (i) all information regarding [...***...], and which is necessary for the third party
supplier to manufacture and recover such Biomolecule, as well as the [...***...]; and (ii) for [...***...], Verenium will provide Syngenta with [...***...]. In addition, within thirty (30) days of the
Effective Date, Verenium agrees to provide Syngenta with all materials that Syngenta has paid for Verenium to manufacture, but that have not yet been delivered as of the Effective Date of this Agreement as set forth in Exhibit E, solely for
use by Syngenta in exercising the Syngenta Rights. Verenium will also deliver to Syngenta [...***...], solely for use by Syngenta in exercising the Syngenta Rights. 
 8.      Information Delivery. Within thirty (30) days of the Effective Date of
this Agreement (which may be extended by Verenium to up to sixty (60) days after the Effective Date as necessary to allow sufficient time for delivery), Verenium will deliver to Syngenta electronic copies of the following solely for use by
Syngenta in exercising the Syngenta Rights: (i) all information, including but not limited to all [...***...], and (ii) all [...***...] that Verenium was obligated to have provided to Syngenta pursuant to the
terms of and during the term of the LRA and the Collaboration Agreement, and which have not already been provided to Syngenta as set forth in Exhibit F. Within thirty (30) days of the Effective Date of this Agreement, Syngenta will
deliver to Verenium electronic copies of all [...***...] that Syngenta was obligated to have provided to Verenium and which have not already been provided to Verenium pursuant to the terms of and during the term of the LRA and the
Collaboration Agreement as set forth in Exhibit F to the extent containing Collaboration Materials and solely for use by Verenium in exercising the Verenium Rights. During the delivery period specified above, but in no event later than sixty
(60) days after the Effective Date, upon Syngenta’s request, the Parties will meet in person to facilitate the transfer of all such information described in this Section 8. The Parties shall make commercially reasonable efforts to
cooperate and provide such information in a timely manner, and each Party agrees to comply with any reasonable request of the other Party to meet to discuss and review any information or material transfer necessary to comply with the transfer
obligations under this Agreement. 
 9.      [Reserved.] 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 9	  	  

		  	  	

 10.        Patent
Prosecution. 
 10.1      Ownership of Intellectual Property Rights.

              (a)      Syngenta or its Affiliates shall retain all ownership rights to all Patent Rights, Know-How and materials filed in the name
of, made or owned by Syngenta or its Affiliates as of, or acquired by Syngenta or its Affiliates as of, the Effective Date, including rights owned by or assigned to Syngenta pursuant to the LRA, including, without limitation, the patents and patent
applications set forth in Exhibit B. 
              (b)      Verenium or its Affiliates shall retain all ownership rights to all Patent Rights, Know-How and materials filed in the name
of, made or owned by Verenium or its Affiliates as of, or acquired by Verenium or its Affiliates as of, the Effective Date, including rights owned by or assigned to Verenium pursuant to the LRA, including, without limitation, Verenium’s
proprietary nucleic acid libraries and all improvements to Verenium’s discovery and evolution technologies, and all its screening assays, robotic devices and software related thereto. 
 10.2      Filing of Patents. Subject to the provisions of Section 10.3, Verenium
shall have the right, in its own discretion, to file for, prosecute and maintain (including the defense of interferences, oppositions and similar proceedings) all Verenium Patent Rights and Verenium Improvement Patent Rights. Syngenta shall have the
right, in its own discretion, to file for, prosecute and maintain (including the defense of interferences, oppositions and similar proceedings) all Syngenta Patent Rights and Syngenta Improvement Patent Rights. Each Party agrees to cooperate fully
in the preparation, filing, and prosecution of any Patent Rights under this Agreement, including without limitation executing all papers and instruments or requirement its employees or consultants, to execute such papers and instruments as may be
reasonably required, so as to enable the other Party to apply for and to prosecute its Patent Rights in any country. 
 10.3      Notice of Discontinued Prosecution. If at any time Verenium does not wish to file or wishes to discontinue the prosecution or maintenance of any patent application or patent within the Verenium
Patent Rights licensed to Syngenta under Section 2.1 filed in any country, on a country-by-country basis, Verenium shall (and shall obligate its outside patent counsel to) give notice of such intention to Syngenta at least sixty (60) days
prior to the date in which failure to take action would cause such patent application or patent to lapse or otherwise be abandoned. Syngenta will then have the right, but not the obligation, to assume responsibility for the prosecution of any such
Verenium Patent Rights in the applicable country, at its own expense, by giving notice to the Verenium of such intention within thirty (30) days. In such event, Verenium shall assign all of its rights in such Patent Rights to Syngenta and such
rights shall become Syngenta Patent Rights subject to the license granted in Section 2.2. In addition, Verenium hereby agrees to assign to Syngenta the Patent Rights set forth in Exhibit G (the “Assigned Patents”).
Within thirty (30) days following the execution of this Agreement, Verenium shall deliver to Syngenta Patent Rights assignment documents substantially in the form set forth in Exhibit H. Syngenta hereby acknowledges and agrees that it
will not broaden the scope of the claims in the Assigned Patents to claim subject matter beyond [...***...]. In addition, to the extent that the Assigned Patents claim any Biomolecule other than [...***...], Verenium shall
have a perpetual, irrevocable, royalty free, fully paid, exclusive, worldwide license, with the right to sublicense under the Assigned Patents, to make, have made and use such Biomolecules expressed or produced through Microbial Expression and to
use data and information included in the Collaboration Materials, in each case to develop, have developed, make, have made, import, have imported, export, have exported, sell, offer for sale and have sold products which consist of, incorporate or
are made through the use of any such Biomolecules expressed 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 10	  	  

		  	  	

 
or produced through Microbial Expression. In addition, at Verenium’s election and expense, Verenium may file, prosecute and maintain a divisional claiming any Biomolecule other than
[...***...] claimed by the Assigned Patents. 
 10.4      Patent
Enforcement and Defense. In the event either Party becomes aware of (i) any actual or threatened infringement or use of any Syngenta Patent Rights (if the Party becoming aware of the action is Verenium) or Verenium Patent Rights (if the
Party becoming aware of the action is Syngenta), or (ii) any allegation by a Third Party that the exercise of the rights granted to either Party under this Agreement infringes or may infringe the intellectual property rights of such Third Party
(a “Third Party Infringement Claim”), that Party shall promptly notify and provide full details to the other Party provided that neither Party shall be required to provide information if it would waive attorney client privilege or
would be a breach of confidentiality obligations with a third party. Syngenta shall have sole discretion with respect to enforcement, defense and settlement of Syngenta Patent Rights and Syngenta Improvement Patent Rights and Verenium shall have
sole discretion with respect to enforcement, defense and settlement of Verenium Patent Rights and Verenium Improvement Patent Rights. In addition, with respect to (a) infringement of any patent included in the Verenium Patent Rights or any
Third Party Infringement Claim against Verenium that is likely to have a material adverse effect on any product being developed or commercialized by Syngenta or its Affiliates or Sublicensees pursuant to a license granted under this Agreement or
(b) infringement of any patent included in the Syngenta Patent Rights or any Third Party Infringement Claim against Syngenta that is likely to have a material adverse effect on any product being developed or commercialized by Verenium or its
Affiliates or Sublicensees pursuant to a license granted under this Agreement, Syngenta (in the case of subsection (a)) or Verenium (in the case of subsection (b)) shall have the right, at its own expense, to be represented in any action brought
with respect to such infringement by counsel of its own choice, and, if Verenium with respect to such Verenium Patent Rights or Syngenta with respect to such Syngenta Patent Rights fails to bring an action or proceeding prior to the earlier of
(i) a reasonable time following the receipt of notice of such alleged infringement not to exceed [...***...] or (ii) [...***...] before the time limit, if any, set forth in the appropriate laws and regulations for
the filing of such actions, the other Party shall have the right to bring and control any such action at its own expense and by counsel of its own choice, and the Party that owns the Patent Rights shall have the right, at its own expense, to be
represented in any such action by counsel of its own choice. Neither Party shall have the right to settle any patent infringement litigation or claim under this Section 10.4 in a manner that diminishes the rights of the other Party under this
Agreement without the prior written consent of such other Party. 
 10.5      Patent Challenge. Each Party and its Affiliates agrees to support the other in any defense against a challenge to the issuance, validity or enforceability of any of the Patent Rights assigned
to said other Party under this Agreement, the LRA or the Collaboration Agreement. 
 10.6      No Unauthorized Use. Verenium hereby covenants that it will not practice or use the Syngenta Patent Rights or Syngenta Know-How or use any Collaboration Materials or materials or information
provided to it by Syngenta pursuant to the terms of this Agreement, except as expressly permitted in this Agreement. Syngenta hereby covenants that it will not practice or use the Verenium Patent Rights or Verenium Know-How or use any Collaboration
Materials or materials or information provided to it by Verenium pursuant to the terms of this Agreement, except as expressly permitted in this Agreement. Notwithstanding the above, nothing in this Agreement shall prohibit either Party from using
outside the scope of this Agreement information which is in the public domain, unless the use of such information would infringe issued, valid Patent Rights of the other Party. 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 11	  	  

		  	  	

 10.7      No Implied Licenses. No
rights or licenses with respect to any intellectual property owned by Verenium or Syngenta are granted or shall be deemed granted hereunder or in connection herewith, other than those rights expressly granted in this Agreement or in the License
Agreement. 
 11.       Representations and Warranties.  

11.1      Legal Authority. Each Party represents and warrants to the other that it
has the legal power, authority and right to enter into this Agreement and to perform its respective obligations set forth herein, including the exclusive grants of the Syngenta Rights and the Verenium Rights respectively. 
 11.2      No Conflicts. 
     (a)       Syngenta represents and warrants that as of the Effective
Date neither it nor any of its Affiliates is a party to any agreement or arrangement with any third party or under any obligation or restriction, including pursuant to its Certificate of Incorporation or Bylaws, which in any way limits or conflicts
with its ability to fulfill any of its obligations under this Agreement, and that none of them shall enter into any such agreement, or so modify any existing agreement, which would conflict with its ability to fulfill any of its obligations under
this Agreement. 
     (b)       Verenium represents and
warrants that as of the Effective Date neither it nor any of its Affiliates is a party to any agreement or arrangement with any third party or under any obligation or restriction, including pursuant to its Certificate of Incorporation or bylaws,
which in any way limits or conflicts with its ability to fulfill any of its obligations under this Agreement, and that none of them shall enter into any such agreement, or so modify any existing agreement, which would limit or conflict with its
ability to fulfill any of its obligations under this Agreement. 
 11.3      Disclosure. 
     (a)      Verenium hereby represents and warrants that [...***...]. 
     (b)      Syngenta hereby represents and warrants that [...***...]. Syngenta further represents and warrants that
[...***...], other than (i) [...***...], or (ii) [...***...]. 
     (c)      Verenium hereby represents and warrants as of the Effective Date that, other than [...***...], Verenium has no knowledge that [...***...]. 

    (d)      Syngenta hereby represents and warrants as of the
Effective Date that, other than [...***...], Syngenta has no knowledge that [...***...]. 
 11.4      Disclaimer of Warranties. OTHER THAN AS SET FORTH IN THIS AGREEMENT, VERENIUM AND SYNGENTA EXPRESSLY DISCLAIM ANY WARRANTIES OR CONDITIONS, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH
RESPECT TO THE CONFIDENTIAL INFORMATION, PATENT RIGHTS OR KNOW-HOW, RESEARCH RESULTS, TECHNOLOGY, PROGRAM TECHNOLOGY, GENE(S), BIOMOLECULE(S), OR PRODUCTS, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, AND NON-INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR VALIDITY OF ANY TECHNOLOGY, PATENTED OR UNPATENTED. 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 12	  	  

		  	  	

 12.      Confidentiality. 

12.1      Confidential Information. Except as expressly provided herein, the Parties
agree that for a period of ten (10) years from and after the Effective Date of this Agreement, the Receiving Party shall keep completely confidential and shall not publish or otherwise disclose and shall not use for any purpose except for the
purposes contemplated by this Agreement the terms of this Agreement and any Confidential Information of the other Party. The Parties acknowledge and agree that the foregoing restrictions shall not apply to any: 
 (a)      information that is or becomes part of the public domain through no fault of the
Receiving Party or its Affiliates; 
 (b)      information that was obtained
during the term of the LRA or Collaboration Agreement or is obtained after the date hereof by the Receiving Party or one of its Affiliates from any Third Party which is lawfully in possession of such Confidential Information and not in violation of
any contractual or legal obligation to the Disclosing Party with respect to such Confidential Information; 
 (c)      information that is known to the Receiving Party or one or more of its Affiliates prior to disclosure by the Disclosing Party, as evidenced by the Receiving Party’s written records; or 

(d)      information which has been independently developed by the Receiving Party without
the aid or use of any Confidential Information, as shown by contemporaneous written records. 
 12.2      Permitted Disclosures. Confidential Information may be disclosed to employees, agents, consultants and actual or bona fide potential Sublicensees of the Receiving Party or its Affiliates, but
only to the extent reasonably required to accomplish the purposes of this Agreement and only if such employees, agents, consultants and actual or potential bona fide Sublicensees to whom disclosure is to be made are subject to a written obligation
to hold in confidence and not make use of such information for any purpose other than those permitted by this Agreement. Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own
to ensure that such employees, agents, consultants, Affiliates and Sublicensees do not disclose or make any unauthorized use of the Confidential Information. The Receiving Party shall be permitted to disclose Confidential Information in the event
that, and only to the extent that, such information is required to be disclosed to comply with applicable laws or regulations or for regulatory filings to test, register and sell or license products, or develop products for sale or license (such as
disclosure to the United States Securities and Exchange Commission, the United States Environmental Protection Agency, the United States Department of Energy, the United States Food and Drug Administration, or the United States Patent and Trademark
Office, or to their foreign equivalents) (including any disclosure necessary to enable a claim that a Party has the right to file pursuant to the terms of this Agreement), or to comply with a court or administrative order, provided that the
Disclosing Party receives prior written notice of such disclosure and that the Receiving Party takes all reasonable and lawful actions to obtain confidential treatment for such disclosure and, if possible, to minimize the extent of such disclosure.
In addition, each Party may disclose the terms of this Agreement to lenders, investment bankers, and similar financial institutions solely for purposes of financing the business operations of such Party and to third parties in connection with a
potential bona fide merger or acquisition transaction either (i) upon the written consent of the other Party or (ii) if the disclosing Party obtains a signed confidentiality agreement with such financial institution or third party with
respect to such information, upon terms substantially similar to those contained in this Section. 
  

					
	  
	  	Page 13	  	  

		  	  	

 13.        Publicity. All
publicity, press releases and other announcements relating to this Agreement or the transaction contemplated hereby shall be reviewed in advance by, and shall be subject to the approval of, both Parties; provided, however, that either Party may
disclose the terms of this Agreement to the extent required to comply with applicable securities or other laws, in which case the disclosing Party shall use reasonable efforts to provide the non-disclosing Party the opportunity to review and comment
on such disclosure prior to its submission. Verenium shall not reference Syngenta’s products or use Syngenta’s name, trademarks or logos in any Verenium press statements, news releases, advertising, promotional literature, public
presentations, website or other publications of any nature without Syngenta’s prior written approval, not to be unreasonably withheld. Once a particular disclosure has been approved for disclosure, either Party may make disclosures which do not
differ materially therefrom without any need for further consents. All such disclosures shall be copied to the other Party for information. 
 14.        Indemnification and Limitation of Liability. 
 14.1      Syngenta. Syngenta agrees to indemnify, defend and hold harmless Verenium and its Affiliates and Sublicensees and their respective employees, agents,
officers, directors and permitted assigns (each a “Verenium Indemnitee”) from and against any claims, actions or suits by a third party resulting in any liabilities, damages, settlements, claims, penalties, fines, and reasonable
costs or reasonable expenses incurred (including, without limitation, reasonable attorneys’ fees and other expenses of litigation, if any, of Third Parties awarded by the court in a final decision which is not appealed or is unappealable) (any
of the foregoing, a “Claim”) against or incurred by any Verenium Indemnitee to the extent arising out of or resulting from (i) a breach of any of the representations or warranties of Syngenta under this Agreement; or
(ii) a material breach of Syngenta’s obligations under this Agreement; or (iii) the development, manufacture, use, promotion, marketing, sale or other distribution of any product which consists of, incorporates or is made through the
use of Collaboration Materials by Syngenta or its Affiliates or Sublicensees,, or (iv) any liability retained by Syngenta under the [...***...] Agreement or the [...***...] Agreement, as provided in Sections 4 and
5 of this Agreement, except, in each case, to the extent that such Claim arises out of or results from a matter for which Syngenta is entitled to be indemnified by Verenium pursuant to Section 14.2. 
 14.2      Verenium. Verenium agrees to indemnify, defend and hold harmless Syngenta and
its Affiliates and Sublicensees and their respective employees, agents, officers, directors and permitted assigns (each a “Syngenta Indemnitee”) from and against any Claims against or incurred by any Syngenta Indemnitee arising out
of or resulting from (i) a breach of any of the representations or warranties by Verenium under this Agreement; or (ii) a material breach by Verenium of its obligations under this Agreement; or (iii) the development, manufacture, use,
promotion, marketing, sale or other distribution of any product which consists of, incorporates or is made through the use of Collaboration Materials by Verenium or its Affiliates or Sublicensees, except, in each case, to the extent that such Claim
arises out of or results from a matter as to which Verenium is entitled to be indemnified by Syngenta pursuant to Section 14.1. 
 14.3      Procedure. A Verenium Indemnitee or Syngenta Indemnitee (the “Indemnitee”) that intends to claim indemnification under this Section shall
promptly notify the indemnifying Party (the “Indemnitor”) in writing of any Claim in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have the right to participate in, and, to the
extent the Indemnitor so desires, to assume the defense thereof with counsel chosen by Indemnitor, with consent of Indemnitee, which consent shall not be unreasonably withheld. The Indemnitee shall not enter into negotiations or enter into any
agreement with respect to the settlement of any Claim without the prior written approval of 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 14	  	  

		  	  	

 
the Indemnitor, and the indemnity agreement in this Section 14 shall not apply to amounts paid in settlement of any Claim if such settlement is made without the consent of the Indemnitor,
which consent shall not be withheld unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such
Indemnitor of any liability to the Indemnitee under this Section. At the Indemnitor’s request, the Indemnitee under this Section, shall cooperate fully with the Indemnitor and its legal representatives in the investigation and defense of any
action, claim or liability covered by this indemnification and provide full information with respect thereto. 
 14.4      Limitation of Liability. Notwithstanding anything in this Agreement to the contrary, neither Party shall have any liability to the other Party or to any Indemnitee for consequential or special
damages or lost profits, and with respect to Third Party claims, shall only be obligated under Section 14.1 or 14.2, as applicable, to indemnify Indemnitees against actual damages, if any, awarded to a third party or actual settlement amounts,
as applicable. 
 15.        Rights in Bankruptcy. All rights and
licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101
of the U.S. Bankruptcy Code. The Parties agree that each Party that is a licensee of such rights under this Agreement shall retain and may fully exercise its rights and elections under the U.S. Bankruptcy Code. The Parties further agree that, in the
event of the commencement of bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code, the Party hereto which is not a Party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as
appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in their possession, shall be, within ten (10) days of the commencement of such proceeding, delivered to them (i) upon
any such commencement of a bankruptcy proceeding upon their written request therefore, unless the Party subject to such proceeding (or a trustee on behalf of the subject Party) elects to continue to perform all of their obligations under this
Agreement or (ii) if not delivered under (i) above, upon the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefore by the non-subject Party. 
 16.        Governing Law. This Agreement and any dispute arising from
the performance or any breach hereof, including without limitation, any dispute, shall be governed by and construed in accordance with the laws of the State of New York, without reference to conflicts of laws principles. 
 17.        Arbitration. 
 17.1      Consultation. If an unresolved dispute arises out of or relates to this
Agreement, or the breach hereof, either Party may refer such dispute to the Chief Executive Officer of Verenium and Syngenta’s Head of Plant Science (or equivalent position) or his or her nominee for good faith resolution. If such dispute is
not settled within forty-five (45) days of such referral, then either Party may thereafter initiate arbitration in accordance with Section 17.2. 
 17.2      Resolution of Disputes. Except as otherwise provided in this Agreement, including Section 17.6, any dispute, controversy or claim arising out of the
performance of this Agreement, including termination hereof, or any alleged breach hereof which is not settled by mutual consent pursuant to Section 17.1 above, shall be finally settled by binding arbitration as set forth in Section 17.3
below, subject to the right to appeal as provided in Section 17.5. Any arbitration award may be entered in a court of competent jurisdiction for a judicial recognition of the decision and an order of enforcement. 
  

					
	  
	  	Page 15	  	  

		  	  	

 17.3      Procedures. Arbitration of
any dispute, controversy or claim shall be conducted in accordance with the Commercial Arbitration Rules of the American Arbitration Association by three (3) independent, neutral arbitrators appointed in accordance with said rules. Any
arbitration shall be held in New York, New York. The arbitrators shall determine what discovery shall be permitted, consistent with the goal of limiting the cost and time which the Parties must expend for discovery; provided the arbitrators shall
permit such discovery as they deem necessary to permit an equitable resolution of the dispute. Any written evidence originally in a language other than English shall be submitted in English translation accompanied by the original or a true copy
thereof. Except as otherwise expressly provided in this Agreement, the costs of the arbitration, including administrative and arbitrators’ fees, shall be shared equally by the parties and each Party shall bear its own costs and attorneys’
and witness’ fees incurred in connection with the arbitration. A disputed performance or suspended performances pending the resolution of the arbitration must be completed within a reasonable time period following the final decision of the
arbitrators. The arbitrators shall be directed that any arbitration subject to this Section 17.3 shall be completed within one (1) year from the filing of notice of a request for such arbitration. The arbitration proceedings and the
decision shall not be made public without the joint consent of the Parties and each Party shall maintain the confidentiality of such proceedings and decision unless otherwise permitted by the other Party. Any decision which requires a monetary
payment shall require such payment to be payable in United States dollars, free of any tax or other deduction. The Parties agree that the decision shall be the sole, exclusive and binding remedy between them regarding any and all disputes,
controversies, claims and counterclaims presented to the arbitrators, subject to the right to appeal as provided in Section 17.5. 
 17.4      Decision. The arbitrators shall, within fifteen (15) calendar days after the conclusion of the arbitration hearing pursuant to Section 17.3, issue
a written award and statement of decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded. The arbitrators shall be authorized to award compensatory damages, but shall
NOT be authorized (i) to award non-economic damages, such as for emotional distress, pain and suffering or loss of consortium, (ii) to award punitive damages, or (iii) to reform, modify or materially change this Agreement or any other
agreements contemplated hereunder; provided, however, that the damage limitations described in parts (i) and (ii) of this sentence will not apply if such damages are statutorily imposed. The arbitrators also shall be authorized to grant
any temporary, preliminary or permanent equitable remedy or relief the arbitrators deems just and equitable and within the scope of this Agreement, including, without limitation, an injunction or order for specific performance. Judgment on the award
rendered by the arbitrators may be entered in any court having competent jurisdiction thereof. 
 17.5      Limited Right to Appeal. The Parties agree that a final decision of the arbitrators under Section 17.4 shall be subject to a limited arbitral appellate review process as set forth in this
Section 17.5 (an “Appeal”). Within fifteen (15) calendar days of the Parties’ receipt of a final decision of the arbitrators, either Party may make an Appeal of such decision under this Section 17.5 upon written
notice to the other Party. Such notice shall attach a copy of the arbitrators’ decision and the bases for appealing such decision. If neither Party provides such written notice to the other Party within such fifteen (15) day period, then
the decision of the arbitrators under Section 17.4 shall be final, binding, and immediately enforceable. Any decision submitted to an Appeal in accordance with this Section 17.5 shall be heard and decided by a three (3) person
appellate arbitral tribunal (“Tribunal”). The Tribunal shall be constituted using the same selection process as used for arbitrators pursuant to Section 17.3, except that candidates for the Tribunal shall be persons who have
served as district court judges or circuit court judges in the United States federal court system, or who are agreed upon by the Parties, and no person having served as an arbitrator in the arbitration under Section 17.3 may serve on the
Tribunal. Any Appeal proceedings

  

					
	  
	  	Page 16	  	  

		  	  	

 
shall be held in New York, New York, unless the Parties otherwise agree in writing. The Tribunal, in addition to deciding any Appeal, shall have the authority to make a full and final
determination as to any challenge to the Tribunal’s authority to act. The Parties intend for the Appeal to proceed expeditiously and not be used to delay, or have the effect of unduly delaying, the enforcement of the decision of the arbitrators
under Section 17.4 and therefore agree to use the following process. A telephonic, or where feasible in-person, pre-hearing conference shall be held with the Tribunal within fourteen (14) calendar days following the Tribunal being
constituted. Within fourteen (14) calendar days following the pre-hearing conference, each Party shall provide to the other Party and the Tribunal a document stating its position with respect to the Appeal, not to exceed fifty (50) pages
double spaced/letter sized paper (viewed in its totality, and not on a per claim basis), per Appeal. The Tribunal shall determine whether to hold an in-person or telephonic hearing, which in either case shall be held within fourteen (14) days
after the date that the last position document was received by the Tribunal. The Appeal shall be based solely on the written award and statement of decision by the arbitrators delivered under Section 17.4, and no new evidence shall be
submitted. In no event shall the Tribunal, or any Party, contact ex parte, examine, call for testimony, or seek to offer the statement of any of the arbitrators. The standard to be applied to any Appeal based upon an asserted erroneous
finding of fact, or mixed questions of fact and law, shall be whether or not the finding was supported by sufficient evidence presented to meet the standard of proof required in respect of the applicable claim or claims before the arbitrators which
rendered the decision that is subject to the Appeal. The standard to be applied to any Appeal based upon an erroneous finding of law shall be de novo. The Tribunal shall render its written decision within fifteen (15) calendar days
after the hearing. The decision shall be final and binding on the Parties and shall include an award of costs and fees in accordance with Section 17.3. Nothing herein shall be deemed as waiving or affecting, or intending to waive or affect, the
right of any party to challenge the enforceability of an arbitral award based upon the provisions of the Federal Arbitration Act, the New York Convention on the Enforcement of Foreign Arbitral Awards, or any other applicable statute, treaty or
convention. 
 17.6      Excluded Matters. This Section 17 shall not
apply to any dispute, controversy or claim that concerns (a) the validity or infringement of a patent, trademark or copyright; or (b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. 
 17.7      Waiver. By agreeing to this binding arbitration provision, the Parties
understand that they are waiving certain rights and protections which may otherwise be available if a claim between the Parties were determined by litigation in court, including, without limitation, the right to seek or obtain certain types of
damages precluded by this provision, the right to a jury trial, certain rights of appeal, and a right to invoke formal rules of procedure and evidence. 
 18.        Waiver. No failure on the part of Syngenta or Verenium to exercise and no delay in exercising any right under this Agreement, or provided
by statute or at law or in equity or otherwise, shall impair, prejudice or constitute a waiver of any such right, nor shall any partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right,
including without limitation any right under this Agreement or under common law, in equity, by statute, or otherwise. 
 19.        Assignment. This Agreement shall not be assignable by either Party to any third party hereto without the written consent of the other Party
hereto; except either Party may assign this Agreement, without such consent, to an Affiliate of such Party; and either Party may assign this Agreement to an entity that acquires all or substantially all of the business or assets of such Party to
which this Agreement pertains, whether by merger, reorganization, acquisition, sale, or otherwise; provided, however, that, in the event of such merger, reorganization, acquisition, sale or other transaction, no intellectual property of any
acquiring entity that is not a Party on the Effective Date shall be included in

  

					
	  
	  	Page 17	  	  

		  	  	

 
the technology and intellectual property licensed hereunder. The terms and conditions of this Agreement shall be binding on and inure to the benefit of the permitted successors and assigns of the
Parties. 
 20.        Notices. All notices, requests and
other communications hereunder shall be in writing and shall be personally delivered or sent by internationally recognized express delivery service, registered or certified mail, return receipt requested, postage prepaid, in each case to the
respective address specified below, or such other address as may be specified in writing to the other Parties hereto: 
 If to
Syngenta: 
 Syngenta Participations AG 
 Schwarzwaldallee 215 
 CH-4002 
 Basel, Switzerland 
 Attention: President 
 Fax: 41 61 323 7571 
 With a copy to: 
 Syngenta International AG 
 Schwarzwaldallee 215

 CH-4002 
 Basel, Switzerland

 Attention: General Counsel 
 Fax: 41
61 323 7571 
 And with a copy to: 
 Syngenta Biotechnology, Inc. 
 3054 E. Cornwallis Road 
 PO Box 12257 
 Research Triangle Park, NC 27709-2257 
 Attention: Corporate Counsel 
 Fax: 919-597-3035

 If to Verenium: 
 Verenium
Corporation 
 55 Cambridge Parkway, 8th Floor 
 Cambridge, MA 02142 
 Attention: Chief Executive Officer 
 Fax: (617) 674-5353 
 With a copy to: 
 Verenium Corporation 
 55 Cambridge Parkway, 8th
Floor 
 Cambridge, MA 02142 
 Attention: General Counsel 
 Fax: (617) 674-5353 
 Each Party providing notice shall as a matter of courtesy, use reasonable efforts to transmit an electronic or facsimile copy of any such notice, but a failure to do so shall not constitute a failure to
provide notice or a breach of this Agreement. All notices, requests and other communications shall be deemed received

  

					
	  
	  	Page 18	  	  

		  	  	

 
on the date of receipt by the recipient thereof if received prior to 5:00 p.m. in the place of receipt and such is a business day in the place of receipt. Otherwise, any such notice, request or
communication shall be deemed not to have been received until the next succeeding business day in the place of receipt. 
 21.        Independent Contractors. Both Parties hereto are independent contractors and are engaged in the operation of their own respective businesses, and
neither Party hereto is to be considered the agent or partner of the other Party for any purpose whatsoever. Neither Party has any authority to enter into any contracts or assume any obligations for the other Party or make any warranties or
representations on behalf of the other Party. 
 22.        Advice of
Counsel. Verenium and Syngenta have each consulted counsel of their choice regarding this Agreement, and each acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one Party or another and will be construed
accordingly. 
 23.        Severability. In the event that any
provisions of this Agreement are determined to be invalid or unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. The Parties shall in good faith negotiate a
substitute clause for any provision declared invalid or unenforceable, which shall most nearly approximate the intent of the Parties in entering this Agreement. 
 24.        Entire Agreement; Termination of LRA; Modified Term of Research License and Option Agreement; Waiver and Release.

 24.1      Entire Agreement. This Agreement and the Exhibits hereto
constitute the entire agreement, both written or oral, with respect to the subject matter hereof, and, supersede all prior or contemporaneous understandings or agreements, whether written or oral, between Verenium and Syngenta with respect to such
subject matter, including but not limited to the Collaboration Agreement and the LRA, but subject to Section 24.3. 
 24.2      Termination of LRA. The LRA is hereby terminated as of the Effective Date, and the Parties hereby agree and affirm that (i) neither Party shall have any
further obligation with respect to the LRA or the Collaboration Agreement, and (ii) the LRA and the Collaboration Agreement are of no further force or effect and are hereby superseded and replaced in their entirety by this Agreement as of the
Effective Date. 
 24.3      Modified Term of
[...***...] Agreement. The Parties hereby agree that (a) [...***...] Agreement between the Parties, effective as of [...***...] (the “[...***...]”), are hereby amended in their
entirety as set forth below, (b) the obligations of the Parties under [...***...], and (c) except as amended by this Section 24.3, the [...***...] remains in effect in accordance with its terms. 

    “[...***...]      “[...***...]”
means [...***...].” 
     “[...***...]      [...***...]. [...***...].” 
     “[...***...]      [...***...]. This Agreement [...***...].” 
 24.4      Waiver and Release. Each Party hereby generally, irrevocably, unconditionally
and completely releases, acquits and forever discharges the other Party, and all agents, representative, employees, officers, directors, attorneys, successors and assigns thereof, from any and all claims, causes 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 19	  	  

		  	  	

 
of action, damages, losses, attorneys’ fees, costs, whether known or unknown, suspected or unsuspected, matured or unmatured, of every kind and nature, at law or in equity, arising from or
relating to claims or potential claims regarding the scope of the rights and obligations with respect to the Collaboration Agreement or the LRA as of the Effective Date to the extent of the subject matter expressly addressed in this Agreement and
any other claim or potential claim raised in written correspondence between the parties with respect to matters under the Collaboration Agreement or the LRA. Nothing in this Agreement shall be deemed to release, acquit or discharge either Party, or
its agents, representative, employees, officers, directors, attorneys, successors and assigns, from its obligations under this Agreement or any claim arising from any breach of such obligations. 
 25.      Headings. The captions to the several Sections and Subsections hereof are not
a part of this Agreement, but are included merely for convenience of reference only and shall not affect its meaning or interpretation. 
 26.      Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties and their respective legal representatives, successors and
permitted assigns. 
 27.      Counterparts. This Agreement may be executed
in two counterparts, each of which shall be deemed an original and which together shall constitute one instrument. 
  

					
	  
	  	Page 20	  	  

		  	  	

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed by their
authorized representatives as of the Effective Date. 
  

									
	Syngenta Participations AG	 		 	Verenium Corporation
					
	By:	 	 /s/ Michael Kock
	 		 	By:	 	 /s/ Gerald M. Haines II

									
					
	Title:	 	 Global Head IP Seeds
	 		 	Title:	 	 Executive Vice President

					
	Date:	 	 28 October 2009
	 		 	Date:	 	 10/28/09

									
					
	By:	 	 /s/ Pierre-Etienne Boin
	 		 		 	

									
					
	Title:	 	Head Agribusiness Legal & IP	 		 		 	
					
	Date:	 	 28 October 2009
	 		 		 	

  

					
	  
	  	Page 21	  	  

		  	  	

 EXHIBIT A 
 Biomolecules Included in Collaboration Materials 
 [...***...]

  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 22	  	  

		  	  	

 EXHIBIT B 
 Syngenta Patent Rights 
 [...***...] 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 23	  	  

		  	  	

 Exhibit C 
 [...***...] Assignment Agreement 
 [...***...]

  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 24	  	  

		  	  	

 Exhibit D 
 [...***...] Assignment Agreement 
 [...***...]

  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 25	  	  

		  	  	

 Exhibit E 
 Material Production 
  

					
	  
	  	Page 26	  	  

		  	  	

 Exhibit F 
 Information Delivery 
 INFORMATION TO BE DELIVERED TO SYNGENTA: 
 [...***...] 
 INFORMATION TO BE
DELIVERED TO VERENIUM: 
 [...***...] 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 27	  	  

		  	  	

 Exhibit G 
 Assigned Patent Rights 
 [...***...] 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 28	  	  

		  	  	

 Exhibit H 
 Patent Assignment Form 
 The parties will execute standard patent assignment forms
generally acceptable by the patent office in the jurisdiction(s) to which the patent assignment applies. 
  

 *** Confidential Treatment Requested 
  

					
	  
	  	Page 29Form of Value Added Reseller Agreement

 Exhibit 10.17 
 NETWORKED ENERGY SERVICES (NES) SYSTEM 
 VALUE-ADDED
RESELLER (VAR) AGREEMENT 
 between 
 ECHELON CORPORATION (“ECHELON”) 
 550 Meridian Avenue

 San Jose, CA 95126-3422 
 USA 
 and 
              (“VAR”) 
              
              
 Effective Date:
                     
 Agreement Number: NES-VAR                      
 ECHELON enters into this Networked Energy Services Value-Added Reseller Agreement (the “Agreement”) as of the Effective Date to sell to VAR components of ECHELON’s Networked Energy Services
(NES) System (the “NES System”) in accordance with the terms and conditions contained in this Agreement so that VAR may resell its value-added system built on the NES System to VAR’s utility customers. 
 All purchase orders shall be governed by the terms and conditions of this Agreement notwithstanding any preprinted terms and conditions in
any other document. VAR has read, understands and agrees to the terms of this Agreement and the undersigned is duly authorized to sign this Agreement. 
 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed. Each party warrants and represents that its respective signatories whose signatures appear below have been and are on
the date of signature duly authorized to execute this Agreement. 
  

									
	ECHELON	  		  	            
					
	By:	  	  
	  		  	By:	  	  

	Print Name:	  	 Oliver R. Stanfield
	  		  	Print Name:	  	  

	Title: 	  	 Executive Vice President & CFO
	  		  	Title:	  	  

				
	Tel: 408-938-5243	  		  	Tel:	  	                            

	Fax: 408-790-3590 (contracts administration)	  		  	Fax:	  	                            

	Email:cstanfield@echelon.com	  		  	Email:	  	                            

 NES SYSTEM VAR AGREEMENT 
 TERMS AND CONDITIONS 
 1. Definitions. 
 1.1 Added Value means non-ECHELON hardware, software and/or services that represent a significant enhancement and transformation of
the NES System with regard to both value and function. For purposes of this definition, providing financing options is not considered Added Value. 
 1.2 Data Concentrators means ECHELON hardware that provides the connectivity infrastructure between NES System Meters and the NES System Software, as more specifically described in
Exhibit A-2. 
 1.3 Deployment Win shall mean a binding contractual arrangement between VAR and a utility for
the supply of VAR’s Value-Added Utility Solution, which arrangement satisfies the requirements set forth in Section 3.2.2. 
 1.4 Documentation means ECHELON’s Hardware and Software documentation, in hard copy or electronic form. 
 1.5 ECHELON Meter means each ECHELON meter as offered by ECHELON from time to time and as more specifically described on Exhibit A-1. 
 1.6 Hardware means ECHELON Meters and the Data Concentrators. Exhibits A-1 and A-2 contain the current specifications for the Hardware, which specifications may be modified from
time to time by ECHELON, subject to Section 7.2. 
 1.7 Lead Time means the length of time between the receipt by
ECHELON of an order for the Purchase of Hardware from VAR and the shipment of such Hardware to VAR, to account for such matters that include but are not limited to the time needed to acquire, manufacture and assemble Hardware components of the NES
System. 
 1.8 NES System means ECHELON’s Networked Energy Services (NES) System, which is a set of
(i) Software, (ii) Data Concentrators and (iii) ECHELON Meters, that work together to provide the core infrastructure for delivering networked energy services to a Utility, as such system is generally described on
Exhibit A. 
 1.9 NES System API means ECHELON’s application programming interface for the NES System
Software, as defined in the NES System User Guide. 
 1.10 NES System Meters means ECHELON Meters. 
 1.11 NES System Software means ECHELON’s enterprise software that supervises and communicates with Data Concentrators as needed
to deliver networked energy services and provides a standards-based web services interface to the Utility’s enterprise middleware or applications. Exhibit A-3 contains the current specifications for the NES System Software, which
specifications may be amended from time to time by ECHELON. 
 1.12 NES VAR Services means the Start-Up Services set
forth in Section 5.1 and other services relating to the NES System as offered by ECHELON to its value-added resellers for the NES System from time to time. 
 1.13 NES System Provisioning Software means ECHELON’s Windows-based application software that can be used to configure various parameters of Echelon Meters and Data Concentrators. 

1.14 Published Availability Schedule means Echelon’s schedule of Lead Times for products, as the same may be revised by
ECHELON from time to time. 
 1.15 Software means the NES System Software and the NES System Provisioning Software as
described on Exhibit A-3, any diagnostic tool or similar software distributed by ECHELON from time to time to VAR with respect to the NES System, and any copies thereof and Updates and Upgrades provided by ECHELON pursuant to the terms
of its Software Investment Protection (SIP) Service. 
 1.16 Software Investment Protection (SIP) Service shall mean the
program described on Exhibit D. The SIP Service shall refer to the VAR SIP Service and any of the Utility SIP Service offerings, as applicable. 
 1.17 Supervised Meter means each NES System Meter installed as part of VAR’s Value-Added Utility Solution. 

 1.18 Transit Time means, for each shipment of Hardware, the period of time quoted by
ECHELON to VAR from time to time for delivery of such shipment from ECHELON’s shipping facility to the location specified by VAR and by the transportation method specified by VAR. 
 1.19 Update means, if and when available, bug fixes, patches and minor functional enhancements to the then-current version of
Software that ECHELON makes generally available to its customers who are then-current customers for ECHELON’s Software Investment Protection (SIP) Service. 
 1.20 Upgrade means, if and when available, a new release of Software that contains substantial new features and/or additional functionality that ECHELON makes generally available to VAR under the
VAR SIP Service or to VAR’s customers who are then-current customers for a Utility SIP Service that provides for Upgrades. 
 1.21 Utility means an entity that provides electricity to the public or any portion thereof. 
 1.22 VAR Data
Concentrator means a data concentrator assembled by or for VAR that incorporates a Data Concentrator packaged in an appropriate case and combined with an appropriate modem(s) and safety breakers, as adapted for VAR’s target market(s).

 1.23 VAR Support means the telephone and e-mail support provided by Echelon to VAR’s trained development
personnel to support VAR’s development of VAR’s Value-Added Utility Solution and (ii) the second level support provided by ECHELON to VAR’s primary support contacts (as such term is defined in Section 4.5) to support
VAR’s Utility customers that are participants in a Utility SIP program. 
 1.24 VAR’s Value-Added Utility
Solution means VAR’s networked metering solution for Utilities comprised of the NES System and Added Value. 
 2. Scope;
Appointment; Value-Added Requirement. This Agreement sets forth the terms and conditions for VAR’s purchase of the NES System and NES VAR Services in connection with its provision of VAR’s Value-Added Utility Solution to
Utilities. ECHELON hereby appoints VAR as a non-exclusive value-added reseller of the NES System. VAR shall resell the Hardware and redistribute Software only to Utilities and only as part of VAR’s Value-Added Utility Solution. As a condition
of this appointment, VAR will not redistribute the NES System to other resellers, distributors, OEMs or value added resellers. 
 3.
Term. 
 3.1 Initial Term; Renewal Terms. This Agreement shall remain in full force and effect for an
initial period beginning on the Effective Date and ending twenty-four (24) months thereafter (the “Initial Term”). Following the Initial Term, this Agreement may be extended for successive twelve (12) month terms (each, a
“Renewal Term”) by mutual written consent of the parties at least ninety (90) days prior to the end of the Initial Term or then-current Renewal Term, which consent may be withheld in either party’s sole discretion. 
 3.2 Registered Opportunities; Long-Term Deployment Win Support. 
 3.2.1 VAR may register with ECHELON opportunities for sale of VAR’s Value-Added Utility Solution by submitting to ECHELON a document
identifying the potential customer and, in reasonable detail, the opportunity (each, an “Opportunity Notice”). 
 3.2.2 In order for a contractual arrangement between VAR and a Utility for the sale of Value-Added Utility Solution to be deemed to qualify as a “Deployment Win,” such arrangement shall satisfy the following requirements:
(i) VAR has executed a term sheet with or submits a tender to the Utility specified in the corresponding Opportunity Notice regarding the supply of VAR’s Value-Added Utility Solution within three (3) months of the date of the
Opportunity Notice; (ii) VAR has executed a definitive agreement with such Utility for the supply of VAR’s Value-Added Utility Solution (a “Deployment Agreement”) within nine (9) months of the date of the corresponding
Opportunity Notice and (iii) VAR has provided ECHELON with written evidence thereof. 
 3.2.3 Notwithstanding the
non-renewal of this Agreement, ECHELON agrees to supply the NES System to VAR according to the terms of this Agreement in effect as of the date of the corresponding Opportunity Notice in order to support a Deployment Win for the shorter of
(i) the term of the Deployment Agreement or (ii) four (4) years following the date of the corresponding Opportunity Notice; provided that VAR continues to comply with the terms and conditions of this Agreement, including without
limitation, the Minimum Intended Purchase Level set forth in Section 7.6. 
 4. VAR Obligations. VAR represents to ECHELON
that VAR has the technical, marketing and sales resources to develop, promote and sell VAR’s Value-Added Utility Solution. 

 4.1 Development. VAR shall: 
 4.1.1 Intentionally left blank. 
 4.1.2 Assemble or integrate a VAR Data Concentrator; 
 4.1.3 Develop software
applications based upon the NES System Software solely using the NES System API and provide associated integration services. VAR shall provide Echelon with periodic updates regarding such development efforts; 
 4.1.4 Provide value-added services; and 
 4.1.5 Follow any ECHELON-provided testing or certification guidelines. 
 4.2
Traceability. VAR shall comply with the traceability requirements set forth on Exhibit C. 
 4.3 Commitment to
the NES System. 
 4.3.1 Primary Offering. VAR agrees that, during the term of this Agreement, VAR (i) will
aggressively promote VAR’s Value-Added Utility Solution as VAR’s preferred and primary system offering for residential and light commercial metering applications over, without limitation, VAR’s own Legacy Systems and Competitive
Products (as such terms are defined below); (ii) will publicly announce (subject to Section 6.2) and promote VAR’s Value-Added Utility Solution and the NES System as its new, strategic and long-term direction for utility solutions;
(iii) will use best efforts to maximize sales of VAR’s Value-Added Utility Solution to Utilities and to convince Utilities of the value of the NES System; and (iv) will give ECHELON at least ninety (90) days notice prior to
entering into a joint venture, co-marketing, reseller, distribution, OEM, value added reseller or other relationship with a third party to develop, have developed, offer for sale, sell or resell (on its behalf or on behalf of a third party)
Competitive Products. For purpose of this Agreement, “Competitive Products” means networked meter systems or components thereof that are functionally similar to or competitive with the NES System or any Hardware or Software components
thereof that are marketed for use in residential or light commercial settings, but in any case excluding products and services functionally similar to components of the NES System which are targeted for use in heavy commercial and industrial
settings. VAR’s marketing and sales support shall include maintaining a demonstration implementation of VAR’s Value-Added Utility Solution for promotion to prospective Utilities, as well as for training. VAR shall make the demonstration
implementation available for use by ECHELON for marketing and other purposes upon reasonable notice and during normal business hours. 
 4.3.2 Notice of Missing Functionality. If VAR is unable to convince a Utility to accept the NES System or in good faith believes that the NES System cannot meet the technical or business requirements of a specific Utility, VAR will
present to ECHELON a written summary of the “Missing Functionality” describing (i) the function(s) needed that the NES System does not supply, (ii) the volume of meters associated with the needed function(s), (iii) the
timeframe in which the needed function(s) must be available in the NES System to meet the Utility’s needs, and (iv) an estimate of the incremental value of the needed function(s). ECHELON and VAR shall work together in good faith to
determine if the Missing Functionality can be added to the NES System or if the Utility’s needs can be otherwise fulfilled through the NES System. If the parties cannot reach a mutually agreeable conclusion to this process after a reasonable
period of time, VAR shall be free to offer Competitive Products to such Utility and such offer shall not be deemed to be in breach of this Section 4.3. 
 4.3.3 Legacy System Support. For purposes of this Agreement, “Legacy Systems” means those Competitive Products offered for on behalf of VAR prior to the effective date of this Agreement.
VAR shall not be deemed to be in breach of this Section 4.3 to the extent (i) VAR provides support relating to Legacy Systems to customers that existed as of the Effective Date or (ii) otherwise and in good faith provides Legacy
Systems in order to comply with its contractual obligations to third parties in effect as of the Effective Date. 
 4.4 Sales
Training. VAR shall assure that at least two (2) of its then-current personnel have completed NES System sales training as may be required by ECHELON from time to time, at ECHELON’s headquarters in San Jose, California or at another
mutually agreed-upon location. 
 4.5 Support Training. VAR shall designate at least two (2) of its then-current
personnel as primary support contacts who shall serve as the interface between VAR and ECHELON technical support. Each primary support contact will be required to have completed the training provided by ECHELON described on Exhibit E.

 4.6 Support. VAR shall provide front-line support to Utilities and shall participate in the VAR SIP Program described
in Exhibit D. ECHELON’s then-current Exhibit D will apply to any Renewal Term. ECHELON will provide VAR with the then-current Exhibit D at least ninety (90) days prior to the end of the Initial Term or any Renewal
Term. ECHELON reserves the right, but does not assume the responsibility, to directly support any Utility. 

 5. ECHELON Obligations. 
 5.1 Start-Up Services. ECHELON shall provide to VAR the “Start-Up Services” and VAR shall pay to ECHELON the Start-Up
Services Fee, as detailed on Exhibit E. 
 5.2 VAR Support, Software Investment Protection (SIP) Service.
ECHELON shall provide VAR with VAR Support, including the VAR SIP Service and, if so elected by VAR, Utility SIP Service, at the charges referenced in Section 9.3 and in accordance with the terms of Exhibit D. 
 5.3 Documentation. At no charge to VAR, ECHELON shall provide VAR with electronic or CD-ROM copies of the then-available
Documentation, which Documentation shall be in English. Promptly after ECHELON issues any revisions or updates to the Documentation (provided that, in the case of Documentation relating to the SIP Service, VAR participates in such service), ECHELON
will provide a copy thereof to VAR at no charge. In the event Documentation must be translated from English into another language to satisfy VAR’s requirements or for any other reason, ECHELON authorizes VAR to arrange for such translations at
its expense and authorizes VAR to use, reproduce and distribute such translations, but only in connection with the project which required such translations. VAR shall provide copies thereof to ECHELON without compensation and such translated
Documentation, including the copyrights thereto, shall automatically be and remain the property of ECHELON. 
 5.4
Promotional Materials. At no charge to VAR, ECHELON shall provide VAR with electronic copies of certain NES System sales collateral (“Collateral”) for use in connection with promoting and selling the NES System. VAR may use the
Collateral in accordance with the provisions of Sections 8.2.5 and 12. 
 6. Mutual Obligations. 
 6.1 Cooperation. The parties will cooperate to promote the NES System and VAR’s Value-Added Utility Solution and shall provide
feedback to one another regarding their systems. Either party shall, at the reasonable request of the other party, participate in joint marketing and selling activities during the term of this Agreement, including without limitation, (subject to
reasonable availability of each party’s personnel) meeting with Utilities and reviewing and assisting one another with responses to a Utility’s tender documents in connection with Opportunity Notices. Each party shall bear its own expenses
in connection with such activities. 
 6.2 Publicity. The parties shall issue a mutually agreed-upon press release
announcing the relationship created by this Agreement promptly after the Effective Date. VAR agrees that Echelon may reference VAR as a customer and value-added reseller on its website, in its regulatory filings and in its marketing materials, and
VAR grants to ECHELON a royalty-free, non-exclusive, non-transferable license to use the VAR’s logo for such purposes. 
 6.3 Homologation, Certification and Verification. In the event that applicable local law or regulation requires that any NES Meter and/or Data Concentrator be homologated in a jurisdiction in which homologation has not previously
been obtained, then ECHELON shall have the right, but not the obligation, to proceed to obtain homologation in such jurisdiction. In the event ECHELON does not so elect, then ECHELON shall have no obligation to sell Hardware to VAR for such
jurisdiction if doing to would violate applicable local law or regulation. However, VAR may request ECHELON’s consent for VAR to obtain homologation in such jurisdiction. In the event ECHELON grants such approval, VAR may proceed to obtain
homologation, at VAR’s sole cost and expense, but only in ECHELON’s name. ECHELON and VAR shall reasonably cooperate to obtain homologation, and VAR may request that ECHELON provide, on an as-available basis, e-mail and telephone support,
at no charge to VAR, with respect to such homologation activities. VAR shall also undertake, at its sole cost and expense, any required certification, verification or similar activities or approvals with respect to NES Meters that VAR intends to
purchase under this Agreement, and ECHELON shall have no obligation to undertake or incur any cost or expense with respect to any such activities. In the event ECHELON’s participation is required for such activities and ECHELON agrees to such
participation, then VAR shall be responsible for any costs or expenses incurred by ECHELON in connection with such activities, including any on-going costs or expenses payable by ECHELON in connection with such certification, verification or similar
activity or approval. 
 7. Hardware Purchase. VAR’s purchase of Hardware shall be governed by the following terms:

 7.1 Purchase. For purposes of this Agreement, “Purchase” means each shipment made by ECHELON to VAR during
the Initial Term or any Renewal Term of this Agreement, as applicable. If ECHELON accepts an order during the Initial Term or a Renewal Term that is then shipped by ECHELON to VAR during a

 
subsequent term, then such shipment will constitute a Purchase during the term in which the shipment takes place; provided, however, that if shipment is delayed to a subsequent term by
ECHELON’s inability to deliver such Hardware subject to its Published Availability Schedule (“Delayed Shipment”), then such shipment shall constitute a Purchase during the term in which the order was placed. Software is subject to
license and not sale. Each reference in this agreement to a “Purchase” or “purchase” or “sale” of Software, or like terms, shall refer to a “license” of that Software rather than a transfer of title to that
Software. 
 7.2 Hardware Offering. All of the Hardware components of the NES System that VAR may Purchase under this
Agreement are set forth on Exhibits A-1 and A-2. 
 7.2.1 Additions and Deletions. ECHELON may, from time
to time, in its discretion, add Hardware components to Exhibits A-1 and A-2. Subject to the terms of Section 7.3, ECHELON may delete any Hardware component from Exhibits A-1 and A-2 sixty (60) days after
the date of written notice to VAR of such deletion. 
 7.2.2 Minor Hardware Modifications. ECHELON shall provide VAR with
at least sixty (60) days prior notice of any substitutions or modifications to the specifications or implementations of the Hardware which substitutions or modifications do not adversely affect form, fit or function when such Hardware is used
by VAR in accordance with ECHELON’s specifications and usage guidelines and good engineering practices (“Minor Hardware Modification(s)”). ECHELON shall provide VAR with notice of any Minor Hardware Modifications if such Hardware has
been Purchased by VAR under this Agreement during the six (6) month period immediately preceding such Minor Hardware Modification. Notwithstanding the foregoing, such notice requirement shall not apply to substitutions or modifications to
ECHELON internal documentation or other similar minor changes. 
 7.2.3 Major Hardware Modifications. ECHELON shall
provide VAR with at least sixty (60) days prior notice of any substitutions or modifications to the specifications or implementations of the Hardware which substitutions or modifications do adversely affect form, fit or function when such
Hardware is used by VAR in accordance with ECHELON’s specifications and usage guidelines and good engineering practices (“Major Hardware Modification(s)”), provided that: (a) such notice period shall not apply (but ECHELON will
notify VAR as promptly as reasonably practicable) with respect to Major Hardware Modifications that are required to comply with government regulations or to facilitate safe operation of the Hardware; and (b) such notice shall only be required
if VAR has placed orders for the applicable Hardware under this Agreement during the six (6) month period immediately preceding such Major Hardware Modification. 
 7.3 Last Time Buy. VAR agrees to promptly review such notices of Hardware deletions, Minor Hardware Modifications and Major Hardware Modifications and advise ECHELON within sixty (60) days of
each such notice if the deletion, Minor Hardware Modification or Major Hardware Modification cannot be reasonably accommodated within VAR’s Value-Added Utility Solution. In the event of such determination by VAR, VAR shall have the right to
place an order for the unmodified version of such Hardware during such sixty (60) day period; provided that: (i) VAR’s requested delivery date(s) for such Hardware is within one hundred eighty (180) days after the date of
ECHELON’s notice; (ii) notwithstanding the provisions of Section 7.11, such order may not be canceled, delayed or reduced; (iii) VAR timely pays any non-refundable deposit requested by ECHELON with respect to such order;
(iv) such deletion or Minor or Major Modification was not made to comply with government regulations, to facilitate safe operation of the Hardware or pursuant to the last sentence of Section 16.1; and (v) if such order is for Hardware
which has undergone a Minor Hardware Modification, then VAR’s price for such Hardware shall be subject to a twenty percent (20%) premium charge. ECHELON shall waive such premium charge if VAR (i) can reasonably demonstrate to ECHELON
that such substitution or modification was in fact a Major Hardware Modification or (ii) provides ECHELON with a copy of a notice from a government authority stating that such modification requires VAR to re-homologate its products that use the
modified Hardware. 
 7.4 Forecasts. On a quarterly basis, VAR will provide ECHELON with a one-year non-binding sales
forecast that shall set forth VAR’s estimated monthly requirements for shipment of Hardware by ECHELON’s model number for the upcoming twelve (12) month period. VAR shall provide the first forecast to ECHELON within thirty
(30) days after the Effective Date of the Agreement. Upon thirty (30) days advance written notice, ECHELON will have the right to require monthly updates to the forecasts. 
 7.5 Orders. VAR shall initiate Purchases under this Agreement by submitting written purchase orders which reference this Agreement
and include a requested delivery date(s) that (i) conforms to the appropriate Hardware Lead Times set forth in the Published Availability Schedule and (ii) is no later than the earlier of (x) within six (6) months after the
purchase order date, except as otherwise approved or required by ECHELON, and (y) ninety (90) days after the termination of the then-current term of this Agreement; such purchase orders shall also include ECHELON’s model number, the
applicable price, and requested shipping point to VAR for each Hardware component listed thereon, and in the case of ECHELON Meters, nameplates and labeling

 
specifications using the form specified by ECHELON. The total value of each order for Hardware must equal or exceed minimum order value and minimum shipment quantities communicated by ECHELON to
VAR, in ECHELON’s sole discretion, as currently set forth at Exhibit B. ECHELON shall use commercially reasonable efforts to acknowledge or reject orders within fifteen (15) days of its receipt of VAR’s purchase order. Any
such acknowledgment shall include the acknowledged delivery date(s) to the carrier (in accordance with Section 7.9) (the “Scheduled Delivery Date(s)”). VAR shall be deemed to have accepted the terms of ECHELON’s acknowledgment of
VAR’s purchase order, including the Scheduled Delivery Date(s), unless VAR notifies ECHELON otherwise in writing within five (5) days of VAR’s receipt of such acknowledgment. VAR and ECHELON acknowledge that prior to ECHELON’s
initial acknowledgement with respect to an NES System Meter for which a meter configuration checklist (as referenced in Exhibit B) must be completed, then ECHELON shall not be required to acknowledge VAR’s order until such checklist has been
completed to ECHELON’s satisfaction; VAR shall cooperate with ECHELON to complete such process as soon as reasonably practicable. Except as set forth in Section 7.11, all changes to the order (as modified by ECHELON’s acknowledgment)
require ECHELON’s prior written approval. Orders accepted in one term and shipped in a subsequent term shall be priced at the price in effect at the time of shipment; provided, however, that with respect to a Delayed Shipment (as defined in
Section 7.1), the price shall not be revised upward. 
 7.6 Minimum Intended Purchase Level. VAR intends to
Purchase, and ECHELON agrees to sell to VAR, the minimum annual volume and type of Hardware set forth on Exhibit B, subject to the terms and conditions of this Agreement (the “Minimum Intended Purchase Level”). ECHELON shall
calculate attainment toward VAR’s Minimum Intended Purchase Level by totaling the number of ECHELON Meters listed on Exhibit B Purchased during the applicable term. While VAR may Purchase from ECHELON products that are not listed on
the then-current Exhibits B, such Purchases will not apply toward attainment of VAR’s Minimum Intended Purchase Level. Nothing in this Agreement constitutes a binding commitment on the part of VAR to Purchase the Minimum Intended
Purchase Level, although VAR acknowledges that ECHELON may revise the pricing for products as a result of VAR’s failure to achieve the Minimum Intended Purchase Level, on the terms set forth in Section 9.6, or terminate this Agreement, if
the requirements of Section 18.2 shall have been satisfied. 
 7.7 Acceptance. VAR will accept Hardware if such
Hardware conforms in all material respects to its specifications. VAR shall inspect all Hardware promptly upon receipt thereof and may reject any item that fails to conform in all material respects to the then-current specifications. To reject
Hardware, VAR shall notify ECHELON in writing via fax or e-mail of its rejection and request a Return Material Authorization (RMA) number. Such notice of rejection must be received by ECHELON within (i) in the case of delivery F.O.B.
ECHELON’s shipping facility (Uniform Commercial Code) or F.C.A. ECHELON’s shipping facility (Incoterms 2000) (as provided in Section 7.9), the last day of the period calculated as the Transit Time plus fourteen (14) days and
(ii) in the case of delivery DDP (Incoterms 2000) (as provided in Section 7.9), fourteen (14) days after VAR’s receipt of the Hardware from the carrier. Upon such request, ECHELON shall provide VAR with a RMA number to be
prominently displayed on the shipping container for the defective Hardware. Once ECHELON authorizes the return of any defective product and within five (5) working days of receipt of the RMA number, VAR shall ship such Hardware to the repair
facility, freight prepaid, pursuant to the shipping and other requirements specified by ECHELON in its RMA. VAR’s right to return rejected Hardware under this Section 7.7 shall be void if in ECHELON’s reasonable opinion such defective
condition was caused in whole or in part by accident, fire, or other hazard or by VAR’s misuse, neglect, testing, attempts to repair, or any other reason not caused by ECHELON. If ECHELON confirms the defect, ECHELON shall, at ECHELON’s
option and expense, either provide repaired or replacement the Hardware; otherwise, VAR shall be responsible for all shipping charges. If VAR does not provide notice of defects or return Hardware within the time limits set forth above, then VAR
agrees that the Hardware shall be deemed accepted. The foregoing acceptance procedure shall not relieve VAR’s obligation to pay for the quantity of Hardware that is accepted. For example, if ECHELON ships 1,000 units to VAR and 10 units are
returned pursuant to the aforementioned RMA procedure, then VAR shall be obligated to pay for 990 units as set forth below in Section 9, and ECHELON shall issue an invoice for 10 units when VAR receives and accepts such units pursuant to this
Section 7.7. 
 7.8 Reservation of Property. To the extent applicable under local law, property, legal or
beneficial, in the Hardware will not pass to the VAR until ECHELON has received full payment in cleared funds for all sums owing to ECHELON on any account. Until property passes to VAR, the Hardware shall be held by the VAR as ECHELON’s
fiduciary agent and bailee, the VAR shall keep the Hardware identified as ECHELON’s property, and at the VAR’s expense, on request by ECHELON, immediately return the Hardware or permit ECHELON’s representatives to enter the VAR’s
premises and repossess such Hardware. 

 7.9 Delivery. Except as provided below, delivery will be F.O.B. ECHELON’s
shipping facility (Uniform Commercial Code) for shipments within the United States and F.C.A. ECHELON’s shipping facility (Incoterms 2000) for shipments outside the United States, whereby upon delivery to the carrier, VAR will become
responsible for and bear the entire risk of loss or damage to the products. Title will pass to VAR upon ECHELON’s delivery to the carrier, except as set forth below, and except that the parties acknowledge that title does not pass with respect
to Software and any other software or firmware provided with or in Hardware which is distributed with an accompanying software license agreement, as such products are licensed and not sold. Scheduled Delivery Dates are estimates only. In the
alternative, VAR may elect for delivery to be DDP (Incoterms 2000) at the location designated by VAR, in which case title will pass to VAR upon the carrier’s delivery to the location designated by VAR from time to time. The parties further
acknowledge that pricing for delivery DDP (Incoterms 2000) will necessarily be greater than the pricing contained in Exhibit B, which pricing assumes duty, shipping and insurance are paid by VAR. Upon notice from VAR, which notice shall
include the anticipated quantity of Hardware, the location to which the Hardware is to be shipped and such other information as ECHELON may specify, ECHELON will provide a quote to VAR that covers the incremental pricing for delivery DDP (Incoterms
2000) at the location designated by VAR, which incremental pricing shall include the cost of shipping, insurance, duty and such other costs as ECHELON may specify. 
 7.10 Shipment, Packaging and Mode of Transportation. VAR may provide ECHELON with written shipment and packaging instructions at least fifteen (15) days prior to the Scheduled Delivery Date.
ECHELON will use reasonable efforts to accommodate these instructions. In the absence of specific instructions, ECHELON will ship the Hardware by the method it deems most advantageous and in standard commercial packaging. Transportation and
insurance charges (if insurance is requested by VAR in its written instructions) will be collected or, if prepaid, will be invoiced to and paid by VAR. When special packaging is requested or, in the opinion of ECHELON, required, the costs of the
same, if not set forth on the invoice, will be separately invoiced to and paid by VAR. Equipment held or stored for VAR after an agreed-upon delivery date shall be held or stored at VAR’s sole expense and risk. 
 7.11 Cancellation, Delay or Reduction of Orders. VAR may not cancel, delay or reduce the quantity of Hardware on that portion of an
accepted order with a Scheduled Delivery Date within the applicable Lead Time for such Hardware. VAR may not cancel, delay or reduce the quantity of Hardware on that portion of an accepted order with a Scheduled Delivery Date outside the applicable
lead time without ECHELON’s prior written approval and, in the event ECHELON gives such approval, such change shall be subject to a twenty-five percent (25%) cancellation charge. 
 7.12 New Prices. If under Section 7.11, VAR is permitted a delay in delivery, and if ECHELON has, prior to VAR’s request
therefore, notified VAR of price changes that are effective at the time of the new delivery date, then ECHELON’s price to VAR on Hardware for which delivery was delayed and any penalties due to ECHELON hereunder shall be based upon
ECHELON’s new prices. 
 8. Software Licensing. 
 8.1 Delivery. To the extent not yet delivered, on or before a mutually agreed delivery date, ECHELON shall provide to VAR one (1) gold master copy of each of the NES System Software and the
NES System Provisioning Software, as well as the Documentation. The Software (including any Updates and Upgrades) and Documentation shall be deemed accepted thirty (30) days after receipt by VAR from ECHELON unless VAR provides ECHELON with
evidence of a non-conformity within such thirty (30) day period. 
 8.2 License Grants. 
 8.2.1 ECHELON hereby grants VAR a nonexclusive, nontransferable, worldwide license to use, reproduce, redistribute and sublicense (subject to
the terms of Section 10.1) the NES System Software to Utilities only and only as an integral part of VAR’s Value-Added Utility Solution. 
 8.2.2 ECHELON hereby grants VAR a nonexclusive, nontransferable, worldwide license to use, reproduce, redistribute and sublicense (subject to the terms of Section 10.1) the NES System Provisioning
Software to Utilities only and only as an integral part of VAR’s Value-Added Utility Solution. 
 8.2.3 ECHELON hereby
grants VAR a nonexclusive, non-transferable, worldwide license to use the Software consisting of diagnostic tools or similar software delivered by ECHELON to VAR from time to time for use with the NES System Software. 
 8.2.4 ECHELON hereby grants VAR a nonexclusive, non-transferable, worldwide license (i) to use the NES System API to develop
applications for use with the NES System Software and license and distribute such applications to Utility customers of VAR’s Value-Added Utility Solution and (ii) to permit VAR’s Utility customers to use the NES System API to develop
applications for use with the NES System Software and to execute and use such applications for such Utility’s internal business operations. 

 8.2.5 ECHELON hereby grants VAR a non-exclusive, non-transferable, worldwide license to use
and prepare derivative works of the Collateral for the sole purpose of selling and promoting VAR’s Value-Added Utility Solution, subject to the terms of Section 12. 
 VAR shall distribute the then-current version of the Software in its initial provision of Software to a Utility. VAR may only distribute
Updates and Upgrades to Utilities for which VAR has purchased the Utility SIP Service in accordance with the terms of Exhibit D. 
 8.3 Ownership. VAR acknowledges that the Software is the proprietary and confidential information of ECHELON or its suppliers and that ECHELON or its suppliers retain all right, title, and interest
in and to the Software, including without limitation all copyrights and other proprietary rights. 
 8.4 Restrictions.
VAR agrees not to reverse engineer, reverse assemble, decompile, or otherwise attempt (i) to defeat, avoid, bypass, remove, deactivate or otherwise circumvent any software protection mechanisms in the Software, including without limitation any
such mechanism used to restrict or control the functionality of the Software, or (ii) to derive the source code or the underlying ideas, algorithms, structure or organization from the Software (except that the foregoing limitation shall not
apply to the extent that such activities may not be prohibited under applicable law, in which case, VAR covenants that it will notify ECHELON in writing of the information it requires that it is legally permitted to acquire and will not commence
such activities if ECHELON, within a reasonable time from its receipt of such notice, covenants that it will work in good faith to provide VAR with the information legally required). VAR may not use, modify, reproduce, sublicense, distribute or
otherwise provide to third parties the Software, in whole or in part, other than as permitted under this Agreement. 
 8.5
Notices. VAR shall not remove any copyright notices or proprietary legends of ECHELON and its suppliers contained within the Software. VAR shall include a copyright notice with its VAR’s Value-Added Utility Solution reflecting the
copyright ownership of ECHELON and its suppliers. VAR agrees to indicate in VAR’s documentation for the VAR’s Value-Added Utility Solution that such products contain copyrighted material of ECHELON and its suppliers. 
 9. Prices; Payment; Taxes. 
 9.1 Hardware 
 9.1.1 Price. Subject to Section 7.9 relating to
the incremental cost for delivery DDP (Incoterms 2000), the prices for the Hardware are set forth on Exhibit B. 
 9.1.2
Payment Terms. VAR agrees to pay ECHELON’s invoices within thirty (30) days of the date that title to the Hardware passes to VAR in accordance with Section 7.9, as set forth on ECHELON’s invoice; provided, however that
ECHELON reserves the right to require payment in advance or by letter of credit. In order to satisfy ECHELON’s credit requirements, if VAR’s financial statements are not readily publicly available, then promptly upon request of ECHELON,
VAR shall provide to copies of ECHELON auditor-certified financial statements or a report of Dunn & Bradstreet or a comparable financial reporting service reasonably acceptable to ECHELON. VAR shall not be entitled to withhold payment in
whole or in part on the grounds that it has a claim, counter-claim or set off against ECHELON. 
 9.2 Software.

 9.2.1 Royalties. In consideration for the licenses granted pursuant to Section 8.2, VAR agrees to pay to ECHELON a
royalty of $5.00 per Supervised Meter distributed as part of VAR’s Value-Added Utility Solution (the “Meter Software Royalty”). 
 9.2.2 Payment Terms. ECHELON shall invoice the Meter Software Royalty at the time of invoice for the corresponding Echelon Meter and make a non-refundable prepayment of the Meter Software Royalty
with its payment of invoices under Section 9.2.1 above. Invoices shall be payable within thirty (30) days of the shipment date of the related NES System Meter. 
 9.3 Services; Support. ECHELON shall invoice, and VAR shall pay, fees for NES VAR Services and VAR Support, including the VAR SIP Service and, if so elected by VAR, Utility SIP Service, in
accordance with the terms set forth on Exhibits D and E, respectively. Invoices shall be payable within thirty (30) days, except as otherwise provided in Exhibit D or E. 
 9.4 Currency; Late Payment. All payments are to be made in the currency in which the invoice is rendered. Any invoice in
“$” shall be paid in U.S. dollars. If payment of any amount due to ECHELON becomes overdue, ECHELON may, without prejudice to any other right or remedy (i) charge interest on a day to day basis from the invoice date until payment in
full on the outstanding amount at the rate of one and one-half percent (1.5%) per month or, if less, such other rate as may be the maximum permitted by law, (ii) require payment in advance of delivery of undelivered Hardware or
(iii) suspend delivery of any orders. 

 9.5 Taxes. All prices are exclusive of all foreign, federal, state, municipal,
excise, sales, use, value added (VAT) withholding and other taxes and duties. VAR shall pay any such tax or duty. VAR shall provide ECHELON with official receipts issued by the appropriate taxing authority or such other evidence as is reasonably
requested by ECHELON to establish that such taxes have been paid. If ECHELON is required to pay any such tax or duty, the amount shall be added to VAR’s invoice and VAR shall reimburse ECHELON therefore unless VAR provides ECHELON with a valid
tax exemption certificate. 
 9.6 Price Changes. ECHELON may increase the prices for the NES System, on a
component-by-component basis, no more frequently than once annually provided that VAR meets or exceeds, on a rolling twelve (12) month basis, the Minimum Intended Purchase Level. In the event that VAR does not maintain its Minimum Intended
Purchase Level, ECHELON may adjust pricing for the NES System components in its sole discretion in the next calendar quarter. In the case of any price decreases, the new reduced prices will apply immediately to all new purchase orders placed after
the effective date of the decrease and to unshipped orders or parts thereof previously accepted by ECHELON. In the event that a Utility will provide VAR with a firm written commitment to purchase VAR’s Value Added Utility Solution for a fixed
term, and as a result, VAR seeks firm pricing for the NES System for such fixed term, then ECHELON agrees to consider, in good faith, providing set pricing for the NES System for such fixed term; provided, that nothing herein shall require ECHELON
to agree to any such Base Pricing for any such term. 
 10. Utility Agreements. 
 10.1 Software License Restrictions. VAR shall distribute each copy of the NES System Software and NES System Provisioning Software
pursuant to a written software license agreement between VAR and the Utility that incorporates the terms and conditions set forth on Exhibit F, which terms may be incorporated into the purchase agreement between VAR and such Utility for
VAR’s Value-Added Utility Solution. VAR agrees to use its best efforts to enforce such terms and to inform ECHELON immediately of any known breach of such obligations. ECHELON may modify the terms of Exhibit F upon sixty
(60) days written notice to VAR. After the end of such period, the NES System Software and the NES System Provisioning Software may be distributed only pursuant to the modified terms. 
 10.2 Limitations of Liability. VAR shall distribute VAR’s Value-Added Utility Solution pursuant to an agreement between VAR and
the Utility that incorporates the limitations of liability and disclaimers set forth on Exhibit F. 
 11. Representations and
Warranties. 
 11.1 Representation. Each party represents and warrants that (i) it has the full right,
power, and authority to enter into this Agreement and to fully perform its obligations hereunder and (ii) that its entering into and performance of this Agreement does not violate or conflict with any existing agreement between such party and
any third party. 
 11.2 Hardware Limited Warranty. ECHELON warrants to VAR that the Hardware shall be free from defects
in materials and workmanship for a period of one (1) year after acceptance by VAR in accordance with Section 7.9. ECHELON’s sole and exclusive liability and VAR’s sole remedy under this warranty shall be, at ECHELON’s
option, to provide repaired Hardware or replacement Hardware as provided in Section 11.3. 
 11.3 Hardware Returns.
VAR shall send Hardware with defects covered by the foregoing warranty to ECHELON’s address set forth above or such other address provided by ECHELON from time to time. VAR shall request a Return Material Authorization Number from ECHELON prior
to the return of defective Hardware for repair or replacement by ECHELON. Upon such request, ECHELON shall provide VAR with a RMA number to be prominently displayed on the shipping container for the defective Hardware. Once ECHELON authorizes the
return of any defective hardware and within five (5) working days of receipt of the RMA Number, VAR shall ship such Hardware to the repair facility, freight prepaid, pursuant to the shipping and other requirements specified by ECHELON in its
RMA. VAR acknowledges that replacement Hardware may consist of previously repaired units which may not be identical to the replaced Hardware but will be compatible with the replaced Hardware. This warranty shall be void if in ECHELON’s
reasonable opinion such defective condition was caused in whole or in part by misuse, neglect, testing, attempts to repair, or any other cause beyond normal usage by VAR or its employees, installers, agents, utility personnel or other third parties
engaged by VAR, or by accident, fire, or other hazard. Repair or replacement does not extend the warranty period for such Hardware. 

 11.4 Software Limited Warranty. ECHELON warrants to VAR that the (i) the media
on which the Software is delivered will be free of defects in materials and workmanship for a period of ninety (90) days after delivery to VAR, and (ii) the Software under normal use will perform substantially in accordance with the
Software specifications for a period of ninety (90) days after delivery to VAR. ECHELON’s entire liability and VAR’s exclusive remedy under this warranty will be, at ECHELON’s option, to use reasonable commercial efforts to
attempt to correct or work around errors or to replace the Software with functionally equivalent software. From time to time, ECHELON may make other warranty programs available to VAR. 
 11.5 NES VAR Services. ECHELON shall provide the NES VAR Services in a professional and workmanlike manner. ECHELON’s entire
liability and VAR’s exclusive remedy under this warranty will be, at ECHELON’s option, to use reasonable commercial efforts to perform the NES VAR Services again. 
 11.6 Disclaimer. THE WARRANTIES SET FORTH ABOVE ARE IN LIEU OF, AND TO THE EXCLUSION OF, TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LAW, ALL OTHER WARRANTIES AND CONDITIONS REGARDING ALL HARDWARE, SOFTWARE AND SERVICES PROVIDED HEREUNDER, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTY OF MERCHANTABILITY, SATISFACTORY
QUALITY OR FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT AND THEIR EQUIVALENTS REGARDING THE NES VAR SERVICES, SOFTWARE, HARDWARE OR THEIR USE OF OPERATION ALONE OR IN COMBINATION WITH OTHER VALUE ADDED RESELLERS, ECHELON AND THIRD PARTY
HARDWARE AND SOFTWARE. 
 12. Trademark Usage. 
 12.1 Trademarks. 
 12.1.1 VAR shall include with its marketing, promotional
and advertising materials for VAR’s Value-Added Utility Solution an attribution specified by ECHELON (e.g., the phrase “Powered by ECHELON”) as well as appropriate ECHELON logos (as supplied by ECHELON in camera ready form) and with
reasonable prominence and in accordance with ECHELON’s then-current trademark usage guidelines, a current copy of which is set forth at Exhibit G (the “Trademark Usage Guidelines”). 
 12.1.2 VAR will state that VAR’s Value-Added Utility Solution is built on ECHELON’s NES System, and use in its packaging,
marketing, promotional and advertising materials of VAR’s Value-Added Utility Solution such applicable trademarks, trade names and other marks of ECHELON listed in Exhibit G, as may be amended from time to time (collectively, the
“ECHELON Trademarks”) in accordance with the Trademark Usage Guidelines. Such use will be in conjunction with VAR’s use of its own marks. Before any such use, VAR will provide to ECHELON copies of any such materials, and VAR shall not
so use any to which ECHELON reasonably objects. 
 12.2 Ownership of Mark. VAR acknowledges the ownership of the
Trademarks in ECHELON, agrees that it will do nothing inconsistent with such ownership and that all use of the Trademarks by VAR shall inure to the benefit of and be on behalf of ECHELON. VAR agrees that nothing in this Agreement shall give VAR any
right, title or interest in the Trademarks other than the right to use the Trademarks in accordance with this Agreement and that VAR’s use of the Trademarks and any goodwill in the marks resulting from VAR’s use will inure solely to the
benefit of ECHELON. VAR agrees that it will not challenge the title of ECHELON to the Trademarks or attack the validity of this Agreement. 
 12.3 Quality Standards. VAR agrees to maintain the nature and quality of all services and products rendered and sold by VAR in connection with the Trademarks at a level that meets or exceeds
industry standards and at least commensurate with the quality of services and products previously provided by VAR. 
 12.4
Quality Maintenance. 
 12.4.1 VAR agrees to permit reasonable inspection of VAR’s operation, and to supply ECHELON
with specimens of use of the Trademarks upon request. VAR shall comply with all applicable laws and regulations and obtain all appropriate government approvals pertaining to its resale of the NES System and promotion of VAR’s Value-Added
Utility Solution. 
 12.4.2 VAR shall remedy any deficiencies in: (a) its use of the Trademarks, and/or (b) the
quality of services rendered in conjunction with the Trademarks, upon reasonable notice from ECHELON. 
 12.5 Form of
Use. VAR agrees to use the Trademarks only in the form and manner and with appropriate legends as prescribed from time to time by ECHELON, and not to use any other trademark or service mark in combination with the Trademarks without prior
written approval of ECHELON. The guidelines for using the Trademarks in effect at the Effective Date of this Agreement appear as Exhibit G. ECHELON may, at its sole discretion, change Exhibit G from time to time. 

 12.6 Infringement Proceedings. VAR agrees to notify ECHELON of any unauthorized use
of the Trademarks by others promptly as it comes to VAR’s attention. ECHELON shall have the sole right and discretion to bring infringement or unfair competition proceedings involving the Trademarks. 
 12.7 Other Trademarks. VAR may make appropriate and truthful reference to ECHELON and ECHELON products and technology in VAR’s
company and product literature; provided that VAR property attributes ECHELON’s trademarks, and provided, further, that VAR does not use the name of ECHELON or any ECHELON trademark in its name or in its product name and otherwise complies with
ECHELON’s standard trademark usage guidelines. Except as set forth in Section 12.1, no license is granted, express or implied, under any ECHELON trademarks, trade names or service marks. 
 13. Confidential Information. This Section 13 supersedes the Non-Disclosure Agreement by and between the parties
dated                     . 
 13.1 Definition. The term “Confidential Information” shall mean any information disclosed by one party to the other party in connection with this Agreement that is disclosed in writing,
electronically, orally or by inspection and which a party has a reasonable basis to believe is treated as confidential by the other party. Such Confidential Information may include, but is not limited to, unreleased products, financial information,
sales and marketing plans, the existence of this Agreement (including its terms) and any information disclosed by one party to the other pursuant to this Agreement which is in written, graphic, machine readable or other tangible form and is marked
“Confidential”, “Proprietary” or in some other manner to indicate its confidential nature but does not include customer lists. Confidential Information may also include oral information disclosed by one party to the other
pursuant to this Agreement, provided that such information is designated as confidential at the time of disclosure and reduced to a written summary by the disclosing party, within thirty (30) days after its oral disclosure, which is marked in a
manner to indicate its confidential nature and delivered to the receiving party. 
 13.2 Obligation. Each party shall
treat as confidential all Confidential Information of the other party, shall not use such Confidential Information except as expressly set forth herein or otherwise authorized in writing, shall implement reasonable procedures to prohibit the
disclosure, unauthorized duplication, misuse or removal of the other party’s Confidential Information and shall not disclose such Confidential Information to any third party except as may be necessary and required in connection with the rights
and obligations of such party under this Agreement, and subject to confidentiality obligations at least as protective as those set forth herein. Without limiting the foregoing, each of the parties shall use at least the same procedures and degree of
care which it uses to prevent the disclosure of its own confidential information of like importance to prevent the disclosure of Confidential Information disclosed to it by the other party under this Agreement, but in no event less than reasonable
care. 
 13.3 Exceptions. Notwithstanding the above, the restrictions of this Section 13 shall not apply to
information that: 
 13.3.1 was independently developed by the receiving party without any use of the Confidential Information
of the other party and by employees or other agents of (or independent contractors hired by) the receiving party who have not been exposed to the Confidential Information as demonstrated by written documentation in existence at the time of the
development; 
 13.3.2 becomes known to the receiving party, without restriction, from a third party without breach of this
Agreement and who had a right to disclose it; 
 13.3.3 was in the public domain at the time it was disclosed or becomes in the
public domain through no act or omission of the receiving party; or 
 13.3.4 was rightfully known to the receiving party,
without restriction, at the time of disclosure. 
 13.4 Authorized Disclosure. In addition, each party shall be entitled
to disclose the other party’s Confidential Information to the extent such disclosure is requested by the order or requirement of a court, administrative agency, or other governmental body; provided, that the party required to make the
disclosure shall provide prompt, advance notice thereof to enable the other party to seek a protective order or otherwise prevent such disclosure. Notwithstanding the provisions of this Agreement, each party may disclose the terms of this Agreement
(i) in connection with the requirements of an initial public offering or securities filing or as otherwise required to comply with disclosure requirements for publicly traded companies; (ii) in confidence, to accountants, banks, and
financing sources and their advisors; and (iii) in confidence, in connection with the enforcement of this Agreement or rights under this Agreement. 

 13.5 Residuals. Notwithstanding the foregoing provisions of this Section 13, the
receiving party will have the right to use and exploit Residuals, except that Residuals shall be subject to the same limitations on disclosure as the receiving party would impose on its own confidential information of like value. As used herein,
“Residuals” means ideas, information and understandings that are retained in the memory of an ordinary person skilled in the art, not intent on appropriating the Confidential Information of the disclosing party as a result of his or her
review, evaluation and testing of the Confidential Information of the disclosing party. 
 13.6 Return of Information;
Survival. Upon termination of this Agreement, each party shall, return or destroy and certify the destruction of, any of the other party’s Confidential Information (including all copies thereof) in its possession or control retaining only
sufficient material to fulfill remaining orders and to service the installed base of VAR’s Value-Added Utility Solution customers as mutually agreed-upon by ECHELON and VAR. Section 13.5 shall survive the expiration or termination of this
Agreement, and the other provisions of this Section 13 shall survive for a period from the time of disclosure until the later to occur of the date five (5) years after (i) the date of the last sale under this Agreement, or
(ii) the expiration or termination of this Agreement. 
 13.7 Equitable Relief. If either party breaches any of its
obligations with respect to confidentiality, or if such a breach is likely to occur, the other party shall be entitled to equitable relief, including specific performance or an injunction, in addition to any other rights or remedies, including money
damages, provided by law. 
 14. Limitation of Liability. 
 EXCLUDING CASES WHERE LIABILITY CANNOT BE EXCLUDED OR LIMITED BY APPLICABLE LAW, ECHELON’S TOTAL LIABILITY AND VAR’S TOTAL
REMEDY UNDER OR ARISING IN ANY WAY OUT OF THIS AGREEMENT, WHETHER IN CONTRACT, NEGLIGENCE OR OTHERWISE, INCLUDING BUT NOT LIMITED TO LIABILITY UNDER SECTION 16 SHALL NOT EXCEED IN AGGREGATE THE LESSER OF THE TOTAL AMOUNT PAID UNDER THIS
AGREEMENT BY VAR TO ECHELON FOR PRODUCTS DURING THE PRECEDING TWELVE (12) MONTHS OR ONE MILLION DOLLARS ($1,000,000). IN NO EVENT SHALL ECHELON OR ITS SUPPLIERS BE LIABLE FOR COST OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, LOST PROFITS OR
LOSS OF CONTRACTS, LOSS OF OR CORRUPTION TO DATA, OR ANY OTHER SPECIAL, CONSEQUENTIAL, OR INCIDENTAL DAMAGES ARISING IN ANY WAY OUT OF THIS AGREEMENT, HOWEVER CAUSED, AND ON ANY THEORY OF LIABILITY, INCLUDING NEGLIGENCE. THESE LIMITATIONS SHALL
APPLY EVEN IF A PARTY WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN. THE PARTIES ACKNOWLEDGE AND AGREE THAT THE PRICING AND OTHER TERMS OF THIS AGREEMENT ARE
BASED IN PART UPON THE APPLICATION OF THESE LIMITATIONS TO THIS AGREEMENT. THE FOREGOING LIMITATIONS SHALL NOT APPLY TO ECHELON’S LIABILITY, IF ANY, FOR THIRD PARTY CLAIMS FOR PERSONAL INJURY OR PHYSICAL DAMAGE TO TANGIBLE PROPERTY CAUSED BY
ECHELON’S NEGLIGENCE. 
 15. Safe Operation. 
 VAR ASSUMES RESPONSIBILITY FOR, AND HEREBY AGREES TO USE COMMERCIALLY REASONABLE EFFORTS IN, DESIGNING AND MANUFACTURING VAR’S
VALUE-ADDED UTILITY SOLUTION USING THE NES SYSTEM TO PROVIDE FOR SAFE OPERATION THEREOF, INCLUDING, BUT NOT LIMITED TO, COMPLIANCE OR QUALIFICATION WITH RESPECT TO ALL SAFETY LAWS, REGULATIONS AND AGENCY APPROVALS, AS APPLICABLE. 
 16. Indemnities. 
 16.1 By ECHELON. ECHELON agrees to defend or settle any action brought against VAR to the extent it is based on a claim that the NES System infringes a third party United States or European Union patent, copyright, trademark, design
or trade secret. ECHELON will pay any resulting liabilities, damages and costs payable by VAR to such third party in any such action; provided that VAR (i) promptly (within twenty (20) days) notifies ECHELON in writing of any such claim
and ECHELON has sole control of the defense and all related settlement negotiations and (ii) cooperates with ECHELON, at ECHELON’s expense in defending such claim. ECHELON shall have no liability for any claim based upon:
(i) negligence in the design or manufacture of VAR’s Value-Added Utility Solution; (ii) breach of any express, implied or statutory warranty to a third party with respect to the VAR’s Value-Added Utility Solution;
(iii) strict liability with respect to the VAR’s Value-Added Utility Solution; (iv) infringement of the intellectual property rights of any third party (except with

 
respect to the Software) arising out of the use, operation or combination of third party or VAR products or services with non-ECHELON programs, data, equipment or documentation if such
infringement would have been avoided but for such use, operation or combination; (v) except set forth herein, the manufacture, use, distribution, license, sublicense or sale of VAR’s Value-Added Utility Solution; (vi) VAR’s or
end users’ modification, use, license, sublicense or distribution of the NES System, and use of other than the then current, unaltered version of the NES System after ECHELON has notified VAR in writing that a prior version should no longer be
used because of a potential infringement claim, unless the infringing portion is also in the then current, unaltered release; (vii) VAR’s or its agent’s activities after ECHELON has notified VAR that ECHELON believes such activities
may result in such infringement; (vii) any modifications or marking not specifically authorized in writing by ECHELON; (ix) VAR’s use of any trademarks other than as set forth in Section 12; (x) third party products and
services; or (xi) any applications developed by or for VAR using the API (collectively, the “Excluded Claims”). This indemnity shall also not apply to Software or any software or firmware provided with or in Hardware that is
distributed with an accompanying software license agreement (and any indemnity set forth in such agreement shall apply). If, at any time, the NES System becomes, or in the opinion of ECHELON may become, the subject of a claim of infringement of any
United States or European Union patent, copyright, trademark, design or trade secret, ECHELON may, at its option (i) procure for VAR the right to continue using such NES System; (ii) replace or modify such NES System; or (iii) accept
return of such NES System and refund the purchase price therefore, less a reasonable sum for use, and terminate this Agreement with respect to such NES System. The provisions of Section 7.3 (regarding Last Time Buy rights) shall not apply to
Hardware that is, or in the opinion of ECHELON may be, infringing. 
 16.2 Limitation. ECHELON’S LIABILITY UNDER
THIS SECTION 16 SHALL NOT EXCEED THE LESSER OF THE TOTAL AMOUNT PAID UNDER THIS AGREEMENT BY VAR TO ECHELON FOR THE PRODUCTS DURING THE PRECEDING TWELVE (12) MONTHS OR ONE MILLION DOLLARS ($1,000,000). THE FOREGOING STATES THE ENTIRE
LIABILITY AND OBLIGATION OF ECHELON WITH RESPECT TO INFRINGEMENT OR CLAIMS OF INFRINGEMENT OF ANY PATENT, COPYRIGHT, DESIGN, TRADE SECRET, OR OTHER INTELLECTUAL PROPERTY OR PROPRIETARY RIGHT BY THE PRODUCTS OR ANY PART THEREOF. 
 16.3 By VAR. Except to the extent that ECHELON is obligated to indemnify VAR under Section 16.1 above, VAR agrees to indemnify,
hold harmless and defend (with counsel free of any conflict of interest between such counsel and ECHELON or any other indemnitee hereunder) ECHELON and its directors, officers, employees, agents and subsidiaries from and against any and all claims,
allegations, proceedings, losses, liabilities, costs and expenses (including reasonable attorneys’ fees) arising out of or in connection with the VAR’s Value-Added Utility Solution or the Excluded Claims. 
 17. Grant Back. As used in this Section 17, “VAR NES Related Patents” means any current or future patents owned or controlled
by VAR that claim or cover any of the functionality in or any embodiment of the NES System or any components thereof, whether hardware or software, or any Improvement thereto, and “Improvement” means any improvement in the existing
features or functions of the NES System or any components thereof, whether hardware or software, and any enhancement of the features or functions of the NES System or any components thereof, whether hardware or software (including any software to
integrate the Software with VAR’s application developed pursuant to Section 8.2.3, but not the application itself). VAR hereby grants to ECHELON a non-exclusive, worldwide, irrevocable, perpetual, royalty-free, fully paid license, under
the VAR NES Related Patents, to make, have made, use, sell, offer for sale, import and sublicense Improvements as part of the NES System and new versions thereof. For purposes of clarification, VAR is not required to deliver to ECHELON any source
code, schematics, or other materials developed by or for VAR. 
 18. Termination. 
 18.1 This Agreement may be terminated immediately by either party through written notice under any of the following conditions: 

18.1.1 The other party ceases to carry on business as a going concern, becomes the object of the institution of voluntary or involuntary
proceedings in bankruptcy or liquidation, or a receiver is appointed with respect to a substantial part of its assets, or any event analogous to the foregoing in any jurisdiction; 
 18.1.2 The other party breaches any of the material provisions of this Agreement and fails to remedy such breach within thirty
(30) days after written notification by the other party of such breach; or 
 18.1.3 As set forth in Section 20.14.

 Notwithstanding the foregoing, this Agreement may be terminated immediately by ECHELON in
the event of VAR’s breach of Section 8 (Software Licensing) or by either party in the event of a breach of Section 13 (Confidential Information). 
 18.2 ECHELON may terminate this Agreement, in its sole discretion, if VAR fails to achieve its quarterly Minimum Intended Purchase Level for two (2) consecutive quarters or if ECHELON, in its sole
discretion, determines that VAR has failed to comply with the provisions of Section 4.3. 
 18.3 No Liability for
Expiration or Termination. VAR AGREES THAT, IN THE EVENT OF EXPIRATION OR TERMINATION OF THIS AGREEMENT FOR ANY REASON, IT SHALL HAVE NO RIGHTS TO DAMAGES OR INDEMNIFICATION OF ANY NATURE, SPECIFICALLY INCLUDING COMMERCIAL SEVERANCE PAY, WHETHER
BY WAY OF LOSS OF FUTURE PROFITS, EXPENDITURES FOR PROMOTION OF ECHELON’S NES SYSTEM OR NES VAR SERVICES, OR OTHER COMMITMENTS IN CONNECTION WITH THE BUSINESS AND GOODWILL OF VAR. VAR EXPRESSLY WAIVES AND RENOUNCES ANY CLAIM TO COMPENSATION OR
INDEMNITIES FOR ANY TERMINATION OF A BUSINESS RELATIONSHIP. 
 18.4 Survival of Certain Terms. The provisions of Sections
3.2.2, 3.2.3, 8.3, 9, 10, 11, 12.2, 13, 14, 15, 16, 17, 18.2, 18.3, 19 and 20 shall survive the expiration or termination of this Agreement for any reason. All agreements between Utilities and VAR for VAR’s Value-Added Utility Solution provided
under the provisions of this Agreement shall survive the expiration or termination of this Agreement for any reason, in accordance with their terms. All other rights and obligations of the parties shall cease upon expiration or termination of this
Agreement. In addition, the terms of this Agreement shall apply with respect to post-termination sales in support of Deployment Wins. 
 19.
Project Amendments. If VAR reasonably believes that, in connection with a project for a Utility that is the subject of an Opportunity Notice, the requirements of a specific tender issued by such Utility (a copy of which must be
delivered by VAR to ECHELON) could best be met by a modification of each parties respective obligations under this Agreement with respect to that particular tender, the parties agree negotiate in good faith for, and use commercially reasonable
efforts to agree to modified terms and conditions (a “Project Amendment”) that shall apply only to the particular tender that is the subject of the Project Amendment. VAR acknowledges (i) that ECHELON shall have no obligation to agree
to any specific warranties, penalties, penalty amounts or other terms that are the same as the corresponding conditions specified in the Utility’s tender documents and (ii) ECHELON may require an increase in the pricing for products and
services purchased pursuant to this Agreement as part of such a Project Amendment. Nothing in this Section 19 shall obligate either party to enter into a Project Amendment for any specific tender. The parties agree that terms of a Project
Amendment shall prevail in order to resolve conflicts, if any, between the terms of a Project Amendment and this Agreement with respect to the tender, project or request for proposal covered by such Project Amendment. 
 20. General. 
 20.1
Governing Law. This Agreement shall be governed by the laws of the State of California, including its Uniform Commercial Code and excluding the U.N. Convention on the International Sale of Goods, but without reference to conflicts of law
principles. 
 20.2 Disputes; Arbitration. Either party may institute a suit for injunctive relief to prevent a breach of
this Agreement (plus an award of costs and attorneys’ fees), and ECHELON may institute an action for payment under this Agreement (plus costs and attorneys’ fees), in any court of competent jurisdiction; as to any such suit, both parties
accept, and hereby submit, to the non-exclusive in personam jurisdiction of any state or federal court in San Francisco or Santa Clara County, California. Any other dispute arising out of or in connection with or relating to this Agreement shall be
determined by binding arbitration conducted in accordance with this Agreement. 
 20.2.1 Except as set forth in
Section 20.2 above, disputes shall be finally settled by binding arbitration by an arbitral tribunal consisting of three arbitrators appointed by the Court of Arbitration of the International Chamber of Commerce (ICC). The arbitration tribunal,
including all staff, all witnesses, and attending non-parties, shall be legally bound by agreements and orders to prevent disclosure of any information which may be disclosed to them in connection with arbitration proceedings conducted hereunder.
The arbitration shall take place in San Francisco or Santa Clara County, California, in the English language only and according to the Rules of conciliation and arbitration of the ICC. The arbitrator shall apply California law and excluding the U.N.
Convention on the International Sale of Goods, but without reference to conflicts of laws principles, to the merits of the dispute but the arbitrator shall not in any circumstances have the power or authority to add to or detract from this
Agreement, to find any provision of this Agreement unconscionable or otherwise unenforceable or to award any party punitive damages or any other remedy or damages prohibited by this Agreement. 

 20.2.2 The joint costs of arbitration (such as court reporting costs and the
arbitrator’s fees) shall be borne equally by the parties except that the arbitrator, in his or her discretion, may award such costs and/or reasonable attorney’s fees and other costs to be paid by the losing party to the prevailing party.

 20.2.3 Judgment on the arbitrators’ award may be entered in any court having jurisdiction. 
 20.3 No Waiver. No modification to this Agreement, or any waiver of any rights, shall be effective unless mutually assented to in
writing and the waiver of any breach or default shall not constitute a waiver of any other right hereunder or any subsequent breach or default. 
 20.4 Assignment. Neither party may assign this Agreement, by operation of law or otherwise, without the prior written consent of the other party, which consent shall not be unreasonably
withheld. Either party may assign this Agreement without the consent of the other party to its wholly-owned subsidiaries or to a third party which acquires all or substantially all of that portion of its business or assets to which this
Agreement pertains, whether by merger, reorganization, acquisition, sale or otherwise. 
 20.5 Invalidity. If any
provision in this Agreement shall be held to be invalid or unenforceable the remainder of this Agreement shall remain valid and enforceable. 
 20.6 Independent Contractors. Each party shall provide the services under this Agreement as an independent contractor. Each party is an independent contractor and as such does not have any
authority to bind or commit the other to any third party. Nothing herein contained shall be deemed or construed to create a joint venture, partnership, agency, or franchisor/franchisee relationship between the parties for any purpose. 
 20.7 Purchases By Related Companies. A parent corporation of VAR which owns more than fifty percent (50%) of the voting
stock or other equity interests in VAR, and subsidiaries and affiliates of VAR or such parent in which VAR or such parent owns more than fifty percent (50%) of the voting stock or other equity interests, shall be authorized to order Hardware
and exercise any other rights of VAR under this Agreement; provided, that such parent, subsidiary or affiliate agrees in writing to be bound by the terms of this Agreement as if it were a party hereto. VAR hereby guarantees the performance of
all obligations hereunder of any such parent, subsidiary or affiliate, and upon request of ECHELON, shall execute such guarantee or other agreement as ECHELON may request to evidence such guarantee. VAR shall create and update Exhibit H
from time to time to add the name and address of any such parent, subsidiary or affiliate. 
 20.8 Entire Agreement. This
Agreement and any software license agreement accompanying the Software is the complete agreement between the parties hereto concerning the subject matter of this Agreement and replaces any prior oral or written communications between the parties.
There are no conditions, understandings, agreements, representations or warranties, expressed or implied, which are not specified herein. This Agreement may only be modified by a written document executed by the parties hereto and replaces and
supersedes any prior agreements and communications, oral or in writing, between the parties. VAR confirms that it does not rely on any representation made but not expressly included in this Agreement. 
 20.9 Third Party Beneficiaries. Except as specifically set forth herein, this Agreement does not create any third party beneficiary
between a party to this Agreement and any third party. 
 20.10 Governmental Approvals. VAR represents and warrants that
no consent, approval or authorization of or designation, declaration or filing with any governmental authority is required in connection with the valid execution and delivery of this Agreement. Alternatively, if any such actions are required, VAR
agrees to use its best efforts to obtain such consent, approval or authorization and agrees to complete such designation, declaration or filing. ECHELON will cooperate as reasonably requested by VAR for the completion of such required actions. VAR
promptly will provide ECHELON with copies of any documents in connection with such actions. 
 20.11 Foreign Corrupt
Practices Act. In conformity with the United States Foreign Corrupt Practices Act and with ECHELON’s established corporate policies regarding foreign business practices, VAR and its employees and agents shall not directly or indirectly make
and offer, payment, promise to pay, or authorize payment, or offer a gift, promise to give, or authorize the giving of anything of value for the purpose of influencing an act or decision of an official of any government (including a decision not to
act) or inducing such a person to use his influence to affect any such governmental act or decision in order to assist ECHELON or VAR in obtaining, retaining or directing any such business. 

 20.12 Compliance with Laws. Each party shall comply with all applicable laws,
regulations and rules of any governmental authority having jurisdiction and shall obtain all necessary permits, licenses and consents of governmental authorities necessary for the manufacture, sale, export, import or other performance contemplated
by this Agreement. Each party hereby represents and warrants that no consent, approval or authorization of or designation, declaration or filing with any governmental authority is required in connection with the valid execution, delivery and
performance of this Agreement. 
 20.13 Export Controls. VAR agrees not to export, or re-export, or cause to be exported
or re-exported, any Hardware or Software received hereunder, or the direct product of such Hardware or Software, to any country to which, under the laws of the United States, VAR is or might be prohibited from exporting such technology or the direct
product thereof. 
 20.14 Force Majeure. Except for VAR’s payment obligations to ECHELON, neither party shall be
liable to the other for its failure to perform any of its obligations hereunder (excluding a payment obligation) during any period in which such performance is delayed by circumstances beyond its reasonable control including, but not limited to,
fire, flood, earthquake, war, embargo, strike, riot, inability to secure materials and transportation facilities, supplier failures or delays due to industry conditions (e.g., shortages or allocations) or the intervention of any governmental
authority. If such delaying cause shall continue for more than sixty (60) days, the party injured by the inability of the other to perform shall have the right upon written notice to terminate this Agreement. 
 20.15 English Language. This Agreement is in the English language only, which language shall be controlling in all respects. No
translation, if any, of this Agreement into any other language shall be of any force or effect in the interpretation of this Agreement or in determination of the interests of either party hereto. 
 20.16 Notice. Any notices required for or permitted by this Agreement are effective as follows: (i) immediately when delivered
by personal delivery to the individuals identified below, (ii) upon written verification of receipt when delivered by overnight courier, or (iii) upon verification of receipt when delivered by certified or registered mail, return receipt
requested. All notices must be in writing, sent via one of the methods indicated in this Section, and sent to the addresses set forth on the cover page of this Agreement or to such other address that the receiving party may have provided for the
purpose of notice in accordance with this Section 20.16. In the case of ECHELON, such notices shall be addressed to the General Counsel at the address first set forth on the cover page, and in the case of VAR, such notices shall be addressed to
the VAR Contact set forth on the cover page at the address set forth on the cover page. Either party may change its designated addressee by written notice to the other party in accordance with the provisions of this Section 20.16. 

20.17 Execution in Counterparts and By Facsimile. This Agreement may be executed in counterparts, each of which will be deemed an
original and all of which together will constitute one instrument. This Agreement may be executed and delivered by facsimile and the parties agree that such facsimile execution and delivery shall have the same force and effect as delivery of an
original document with original signatures, and that each party may use such facsimile signatures as evidence of the execution and delivery of this Agreement by all parties to the same extent that an original signature could be used. 
 20.18 Product Evaluation. From time to time, in its sole discretion, ECHELON may offer VAR the opportunity to receive new or modified
versions of hardware or software Products prior to their commercial release by ECHELON (“Pre-Release Products”), at no charge or for such charge as ECHELON may specify. VAR may, but shall have no obligation to, accept ECHELON’s offer
receive Pre-Release Products. If VAR elects to receive any Pre-Release Products, then the following terms shall apply: 
 20.18.1 VAR acknowledges that the Pre-Release Products have not been commercially released, and that VAR shall use such Pre-Release Products with the understanding that such Pre-Release Products may not have passed safety agency tests. VAR
will indemnify and hold harmless Echelon from and against all claims, costs, losses, damages and expenses, including attorney’s fees, arising out of or relating to VARs use of the Pre-Release Products. Due to the nature of development work,
ECHELON cannot be certain as to when or whether errors or discrepancies in the Pre-Release Product(s) may be corrected. VAR acknowledges that the Pre-Release Products may not be offered for sale as then implemented, or in any implementation.

 20.18.2 VAR agrees to comply with such other conditions and restrictions as ECHELON may specify in writing. By way of
examples and not limitation, (i) ECHELON may require that the Pre-Release Products be limited to (A) VAR’s internal use and evaluation only in its product development laboratory, and ECHELON may limit VAR’s evaluation to only
non-destructive testing, such as testing for accuracy, accuracy under interference and manufacturing quality or (B) marketing, trade show or customer demonstration purposes only; or (ii) ECHELON may limit VAR’s evaluation of the
Pre-Release Products to a specified evaluation period, after which ECHELON may, but shall not be required to, require that VAR either return or purchase or license the Pre-Release Products; or (iii) ECHELON may require that VAR permit use of
the Pre-Release Products only by employees who have appropriate training and education required for the safe operation of untested products. 

 20.18.3 VAR acknowledge agrees that unauthorized copying or disclosure will cause great
damage to ECHELON or to any third party holding any right, title or interest in the Pre-Release Products. The restrictions contained in Section 8 shall apply to the Pre-Release Products and such Pre-Release Products shall be considered as
Confidential Information unless otherwise noted in the accompanying conditions and restrictions. 
 20.18.4 Unless otherwise
noted in the accompanying conditions and restrictions, VAR may make up to one (1) copy of any software that is included in the Pre-Release Products only for back-up purposes, and may not otherwise copy any such software that is included in the
Products. VAR agrees that the Pre-Release Products, all copies thereof and all intellectual property rights therein and thereto are owned by ECHELON or its suppliers, that all copies of software will display ECHELON’s copyright notice. VAR
agrees that it will not distribute to any third party the Pre-Release Products, any portion thereof, or any program derived from the Pre-Release Products, except as permitted by ECHELON in writing. 
 20.18.5 Notwithstanding anything of the other warranties provided for in this Agreement, THE PRE-RELEASE PRODUCTS ARE PROVIDED “AS
IS” WITHOUT WARRANTY OR CONDITION OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE. 
 20.18.6 Contacts. 
  

					
		  	Invoices to be sent to VAR for startup and annual VAR SIP Service shall be addressed to:
			
		  	  
	  	
			
		  	  
	  	
			
		  	VAR designates:	  	
			
		  	  
	  	
			
		  	  
	  	
		
		  	As its primary contact point for cooperative marketing activities.

 END OF TERMS AND CONDITIONS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]